\\n\\n
IntechOpen was founded by scientists, for scientists, in order to make book publishing accessible around the globe. Over the last two decades, this has driven Open Access (OA) book publishing whilst levelling the playing field for global academics. Through our innovative publishing model and the support of the research community, we have now published over 5,700 Open Access books and are visited online by over three million academics every month. These researchers are increasingly working in broad technology-based subjects, driving multidisciplinary academic endeavours into human health, environment, and technology.
\\n\\nBy listening to our community, and in order to serve these rapidly growing areas which lie at the core of IntechOpen's expertise, we are launching a portfolio of Open Science journals:
\\n\\nAll three journals will publish under an Open Access model and embrace Open Science policies to help support the changing needs of academics in these fast-moving research areas. There will be direct links to preprint servers and data repositories, allowing full reproducibility and rapid dissemination of published papers to help accelerate the pace of research. Each journal has renowned Editors in Chief who will work alongside a global Editorial Board, delivering robust single-blind peer review. Supported by our internal editorial teams, this will ensure our authors will receive a quick, user-friendly, and personalised publishing experience.
\\n\\n"By launching our journals portfolio we are introducing new, dedicated homes for interdisciplinary technology-focused researchers to publish their work, whilst embracing Open Science and creating a unique global home for academics to disseminate their work. We are taking a leap toward Open Science continuing and expanding our fundamental commitment to openly sharing scientific research across the world, making it available for the benefit of all." Dr. Sara Uhac, IntechOpen CEO
\\n\\n"Our aim is to promote and create better science for a better world by increasing access to information and the latest scientific developments to all scientists, innovators, entrepreneurs and students and give them the opportunity to learn, observe and contribute to knowledge creation. Open Science promotes a swifter path from research to innovation to produce new products and services." Alex Lazinica, IntechOpen founder
\\n\\nIn conclusion, Natalia Reinic Babic, Head of Journal Publishing and Open Science at IntechOpen adds:
\\n\\n“On behalf of the journal team I’d like to thank all our Editors in Chief, Editorial Boards, internal supporting teams, and our scientific community for their continuous support in making this portfolio a reality - we couldn’t have done it without you! With your support in place, we are confident these journals will become as impactful and successful as our book publishing program and bring us closer to a more open (science) future.”
\\n\\nWe invite you to visit the journals homepage and learn more about the journal’s Editorial Boards, scope and vision as all three journals are now open for submissions.
\\n\\nFeel free to share this news on social media and help us mark this memorable moment!
\\n\\n\\n"}]',published:!0,mainMedia:{caption:"",originalUrl:"/media/original/237"}},components:[{type:"htmlEditorComponent",content:'
After years of being acknowledged as the world's leading publisher of Open Access books, today, we are proud to announce we’ve successfully launched a portfolio of Open Science journals covering rapidly expanding areas of interdisciplinary research.
\n\n\n\nIntechOpen was founded by scientists, for scientists, in order to make book publishing accessible around the globe. Over the last two decades, this has driven Open Access (OA) book publishing whilst levelling the playing field for global academics. Through our innovative publishing model and the support of the research community, we have now published over 5,700 Open Access books and are visited online by over three million academics every month. These researchers are increasingly working in broad technology-based subjects, driving multidisciplinary academic endeavours into human health, environment, and technology.
\n\nBy listening to our community, and in order to serve these rapidly growing areas which lie at the core of IntechOpen's expertise, we are launching a portfolio of Open Science journals:
\n\nAll three journals will publish under an Open Access model and embrace Open Science policies to help support the changing needs of academics in these fast-moving research areas. There will be direct links to preprint servers and data repositories, allowing full reproducibility and rapid dissemination of published papers to help accelerate the pace of research. Each journal has renowned Editors in Chief who will work alongside a global Editorial Board, delivering robust single-blind peer review. Supported by our internal editorial teams, this will ensure our authors will receive a quick, user-friendly, and personalised publishing experience.
\n\n"By launching our journals portfolio we are introducing new, dedicated homes for interdisciplinary technology-focused researchers to publish their work, whilst embracing Open Science and creating a unique global home for academics to disseminate their work. We are taking a leap toward Open Science continuing and expanding our fundamental commitment to openly sharing scientific research across the world, making it available for the benefit of all." Dr. Sara Uhac, IntechOpen CEO
\n\n"Our aim is to promote and create better science for a better world by increasing access to information and the latest scientific developments to all scientists, innovators, entrepreneurs and students and give them the opportunity to learn, observe and contribute to knowledge creation. Open Science promotes a swifter path from research to innovation to produce new products and services." Alex Lazinica, IntechOpen founder
\n\nIn conclusion, Natalia Reinic Babic, Head of Journal Publishing and Open Science at IntechOpen adds:
\n\n“On behalf of the journal team I’d like to thank all our Editors in Chief, Editorial Boards, internal supporting teams, and our scientific community for their continuous support in making this portfolio a reality - we couldn’t have done it without you! With your support in place, we are confident these journals will become as impactful and successful as our book publishing program and bring us closer to a more open (science) future.”
\n\nWe invite you to visit the journals homepage and learn more about the journal’s Editorial Boards, scope and vision as all three journals are now open for submissions.
\n\nFeel free to share this news on social media and help us mark this memorable moment!
\n\n\n'}],latestNews:[{slug:"webinar-introduction-to-open-science-wednesday-18-may-1-pm-cest-20220518",title:"Webinar: Introduction to Open Science | Wednesday 18 May, 1 PM CEST"},{slug:"step-in-the-right-direction-intechopen-launches-a-portfolio-of-open-science-journals-20220414",title:"Step in the Right Direction: IntechOpen Launches a Portfolio of Open Science Journals"},{slug:"let-s-meet-at-london-book-fair-5-7-april-2022-olympia-london-20220321",title:"Let’s meet at London Book Fair, 5-7 April 2022, Olympia London"},{slug:"50-books-published-as-part-of-intechopen-and-knowledge-unlatched-ku-collaboration-20220316",title:"50 Books published as part of IntechOpen and Knowledge Unlatched (KU) Collaboration"},{slug:"intechopen-joins-the-united-nations-sustainable-development-goals-publishers-compact-20221702",title:"IntechOpen joins the United Nations Sustainable Development Goals Publishers Compact"},{slug:"intechopen-signs-exclusive-representation-agreement-with-lsr-libros-servicios-y-representaciones-s-a-de-c-v-20211123",title:"IntechOpen Signs Exclusive Representation Agreement with LSR Libros Servicios y Representaciones S.A. de C.V"},{slug:"intechopen-expands-partnership-with-research4life-20211110",title:"IntechOpen Expands Partnership with Research4Life"},{slug:"introducing-intechopen-book-series-a-new-publishing-format-for-oa-books-20210915",title:"Introducing IntechOpen Book Series - A New Publishing Format for OA Books"}]},book:{item:{type:"book",id:"1499",leadTitle:null,fullTitle:"Advances in Immunoassay Technology",title:"Advances in Immunoassay Technology",subtitle:null,reviewType:"peer-reviewed",abstract:"From the basic in vitro study of a specific biomolecule to the diagnosis or prognosis of a specific disease, one of the most widely used technology is immunoassays. By using a specific antibody to recognize the biomolecule of interest, relatively high specificity can be achieved by immunoassays, such that complex biofluids (e.g. serum, urine, etc.) can be analyzed directly. In addition to the binding specificity, the other key features of immunoassays include relatively high sensitivity for the detection of antibody-antigen complexes, and a wide dynamic range for quantitation. Over the past decade, the development and applications of immunoassays have continued to grow exponentially. This book focuses on some of the latest technologies for the development of new immunoassays.",isbn:null,printIsbn:"978-953-51-0440-7",pdfIsbn:"978-953-51-5257-6",doi:"10.5772/1967",price:119,priceEur:129,priceUsd:155,slug:"advances-in-immunoassay-technology",numberOfPages:192,isOpenForSubmission:!1,isInWos:1,isInBkci:!1,hash:"4b1a356482c2cfbe2550488651cb1c59",bookSignature:"Norman H. L. Chiu and Theodore K. Christopoulos",publishedDate:"March 23rd 2012",coverURL:"https://cdn.intechopen.com/books/images_new/1499.jpg",numberOfDownloads:48394,numberOfWosCitations:101,numberOfCrossrefCitations:34,numberOfCrossrefCitationsByBook:7,numberOfDimensionsCitations:106,numberOfDimensionsCitationsByBook:9,hasAltmetrics:1,numberOfTotalCitations:241,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"May 2nd 2011",dateEndSecondStepPublish:"May 30th 2011",dateEndThirdStepPublish:"October 4th 2011",dateEndFourthStepPublish:"November 3rd 2011",dateEndFifthStepPublish:"March 2nd 2012",currentStepOfPublishingProcess:5,indexedIn:"1,2,3,4,5,6",editedByType:"Edited by",kuFlag:!1,featuredMarkup:null,editors:[{id:"98973",title:"Dr.",name:"Norman",middleName:"H. L.",surname:"Chiu",slug:"norman-chiu",fullName:"Norman Chiu",profilePictureURL:"https://mts.intechopen.com/storage/users/98973/images/3664_n.jpg",biography:"Dr. Norman H. L. Chiu is an Associate Professor of Chemistry at the University of North Carolina at Greensboro, USA. He is also an affiliated member of the Joint School of Nanoscience and Nanoengineering in Greensboro, and the Comprehensive Cancer Center at the Wake Forest University. He received his B.Sc. in Chemistry from the University of Liverpool, UK, M.Sc. in Analytical Chemistry from the University of Bristol, UK, and Ph.D. in Biochemistry from the University of Windsor, Canada. He and Dr. Theodore Christopoulos were the first to develop an expressible enzyme-coding DNA label for immunoassays. As a Postdoctoral Research Fellow, he extended his research experience on method development with Dr. Charles R. Cantor at Boston University and Sequenom Inc, USA.",institutionString:null,position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"0",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"University of North Carolina at Greensboro",institutionURL:null,country:{name:"United States of America"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:{id:"120879",title:"Dr.",name:"Theodore K.",middleName:null,surname:"Christopoulos",slug:"theodore-k.-christopoulos",fullName:"Theodore K. Christopoulos",profilePictureURL:"https://mts.intechopen.com/storage/users/120879/images/system/120879.jpg",biography:"Dr. Theodore K. Christopoulos is Professor and Chair, Department of Chemistry, University of Patras, Greece. He received a B.Sc. in Pharmacy (1982) and a Ph.D. in Analytical Chemistry (1987) from the University of Athens, Greece as well as a Postdoctoral Diploma in Clinical Chemistry (1991) from the University of Toronto, Canada. From 1989 to 1992 he was a Postdoctoral Research Associate at the Department of Clinical Biochemistry, University of Toronto. From 1992 to 1999 he worked as Assistant, Associate and Full Professor at the Department of Chemistry & Biochemistry, University of Windsor, Canada. He is the recipient of the 1997 Grannis award for “Excellence in Research and Scientific Publication” from the U.S. National Academy of Clinical Biochemistry.",institutionString:null,position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"0",totalChapterViews:"0",totalEditedBooks:"0",institution:null},coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"902",title:"Diagnostic Immunology",slug:"diagnostic-immunology"}],chapters:[{id:"33738",title:"Recombinant Antibodies and Non-Antibody Scaffolds for Immunoassays",doi:"10.5772/35983",slug:"recombinant-antibodies-and-non-antibody-scaffolds-for-immunoassay",totalDownloads:3942,totalCrossrefCites:0,totalDimensionsCites:2,hasAltmetrics:0,abstract:null,signatures:"Bhupal Ban and Diane A. Blake",downloadPdfUrl:"/chapter/pdf-download/33738",previewPdfUrl:"/chapter/pdf-preview/33738",authors:[{id:"106620",title:"Prof.",name:"Diane",surname:"Blake",slug:"diane-blake",fullName:"Diane Blake"},{id:"106624",title:"Dr.",name:"Bhupal",surname:"Ban",slug:"bhupal-ban",fullName:"Bhupal Ban"}],corrections:null},{id:"33739",title:"Polyacrylonitrile Fiber as Matrix for Immunodiagnostics",doi:"10.5772/38026",slug:"polyacrylonitrile-fiber-as-solid-matrix-for-immunodiagnostics",totalDownloads:2964,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Swati Jain, Sruti Chattopadhyay, Richa Jackeray, Zainul Abid and Harpal Singh",downloadPdfUrl:"/chapter/pdf-download/33739",previewPdfUrl:"/chapter/pdf-preview/33739",authors:[{id:"115239",title:"Dr.",name:"Harpal",surname:"Singh",slug:"harpal-singh",fullName:"Harpal Singh"}],corrections:null},{id:"33740",title:"Interferences in Immunoassays",doi:"10.5772/35797",slug:"interference-in-immunoassays",totalDownloads:17490,totalCrossrefCites:14,totalDimensionsCites:53,hasAltmetrics:1,abstract:null,signatures:"Johan Schiettecatte, Ellen Anckaert and Johan Smitz",downloadPdfUrl:"/chapter/pdf-download/33740",previewPdfUrl:"/chapter/pdf-preview/33740",authors:[{id:"105883",title:"Mr.",name:"Johan",surname:"Schiettecatte",slug:"johan-schiettecatte",fullName:"Johan Schiettecatte"},{id:"113099",title:"Dr.",name:"Ellen",surname:"Anckaert",slug:"ellen-anckaert",fullName:"Ellen Anckaert"},{id:"113100",title:"Prof.",name:"Johan",surname:"Smitz",slug:"johan-smitz",fullName:"Johan Smitz"}],corrections:null},{id:"33741",title:"Fundamentals and Applications of Immunosensors",doi:"10.5772/36947",slug:"fundamentals-and-applications-of-immunosensors",totalDownloads:5015,totalCrossrefCites:15,totalDimensionsCites:34,hasAltmetrics:0,abstract:null,signatures:"Carlos Moina and Gabriel Ybarra",downloadPdfUrl:"/chapter/pdf-download/33741",previewPdfUrl:"/chapter/pdf-preview/33741",authors:[{id:"110541",title:"Dr.",name:"Carlos",surname:"Moina",slug:"carlos-moina",fullName:"Carlos Moina"},{id:"110556",title:"Dr.",name:"Gabriel",surname:"Ybarra",slug:"gabriel-ybarra",fullName:"Gabriel Ybarra"}],corrections:null},{id:"33742",title:"Capabilities of Piezoelectric Immunosensors for Detecting Infections and for Early Clinical Diagnostics",doi:"10.5772/35630",slug:"capabilities-of-piezoelectric-immunosensors-for-detecting-infections-and-for-early-clinical-diagnost",totalDownloads:2985,totalCrossrefCites:3,totalDimensionsCites:5,hasAltmetrics:0,abstract:null,signatures:"Tatyana Ermolaeva and Elena Kalmykova",downloadPdfUrl:"/chapter/pdf-download/33742",previewPdfUrl:"/chapter/pdf-preview/33742",authors:[{id:"105239",title:"Prof.",name:"Tatyana",surname:"Ermolaeva",slug:"tatyana-ermolaeva",fullName:"Tatyana Ermolaeva"},{id:"110385",title:"Prof.",name:"Elena",surname:"Kalmykova",slug:"elena-kalmykova",fullName:"Elena Kalmykova"}],corrections:null},{id:"33743",title:"Label-Free Detection of Botulinum Neurotoxins Using a Surface Plasmon Resonance Biosensor",doi:"10.5772/36629",slug:"label-free-detection-of-botulinum-neurotoxins-using-a-surface-plasmon-resonance-biosensor",totalDownloads:2050,totalCrossrefCites:0,totalDimensionsCites:1,hasAltmetrics:0,abstract:null,signatures:"Hung Tran and Chun-Qiang Liu",downloadPdfUrl:"/chapter/pdf-download/33743",previewPdfUrl:"/chapter/pdf-preview/33743",authors:[{id:"109153",title:"Dr.",name:"Chun-Qiang",surname:"Liu",slug:"chun-qiang-liu",fullName:"Chun-Qiang Liu"}],corrections:null},{id:"33744",title:"Immunoassays Using Artificial Nanopores",doi:"10.5772/34489",slug:"immunoassays-using-artificial-nanopores",totalDownloads:2822,totalCrossrefCites:0,totalDimensionsCites:1,hasAltmetrics:0,abstract:null,signatures:"Paolo Actis, Boaz Vilozny and Nader Pourmand",downloadPdfUrl:"/chapter/pdf-download/33744",previewPdfUrl:"/chapter/pdf-preview/33744",authors:[{id:"100384",title:"Dr.",name:"Paolo",surname:"Actis",slug:"paolo-actis",fullName:"Paolo Actis"},{id:"110152",title:"Prof.",name:"Nader",surname:"Pourmand",slug:"nader-pourmand",fullName:"Nader Pourmand"},{id:"110153",title:"Dr.",name:"Boaz",surname:"Vilozny",slug:"boaz-vilozny",fullName:"Boaz Vilozny"}],corrections:null},{id:"33745",title:"Multiplexed Immunoassays",doi:"10.5772/36994",slug:"multiplexed-immunoassay",totalDownloads:5959,totalCrossrefCites:2,totalDimensionsCites:5,hasAltmetrics:0,abstract:null,signatures:"Weiming Zheng and Lin He",downloadPdfUrl:"/chapter/pdf-download/33745",previewPdfUrl:"/chapter/pdf-preview/33745",authors:[{id:"110781",title:"Dr.",name:"Weiming",surname:"Zheng",slug:"weiming-zheng",fullName:"Weiming Zheng"}],corrections:null},{id:"33746",title:"Multiplexed Bead Immunoassays: Advantages and Limitations in Pediatrics",doi:"10.5772/36024",slug:"multiplexed-bead-immunoassays-advantages-and-limitations-in-pediatrics",totalDownloads:5167,totalCrossrefCites:0,totalDimensionsCites:5,hasAltmetrics:0,abstract:null,signatures:"Emma Burgos-Ramos, Gabriel Ángel Martos-Moreno, Jesús Argente, Vicente Barrios",downloadPdfUrl:"/chapter/pdf-download/33746",previewPdfUrl:"/chapter/pdf-preview/33746",authors:[{id:"106799",title:"Dr.",name:"Vicente",surname:"Barrios",slug:"vicente-barrios",fullName:"Vicente Barrios"},{id:"109231",title:"Dr.",name:"Emma",surname:"Burgos-Ramos",slug:"emma-burgos-ramos",fullName:"Emma Burgos-Ramos"},{id:"109234",title:"Dr.",name:"Gabriel Ángel",surname:"Martos-Moreno",slug:"gabriel-angel-martos-moreno",fullName:"Gabriel Ángel Martos-Moreno"},{id:"109236",title:"Prof.",name:"Jesús",surname:"Argente",slug:"jesus-argente",fullName:"Jesús Argente"}],corrections:null}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},subseries:null,tags:null},relatedBooks:[{type:"book",id:"1697",title:"Serological Diagnosis of Certain Human, Animal and Plant Diseases",subtitle:null,isOpenForSubmission:!1,hash:"981c10c8346033ca6cebd640a12ed3d7",slug:"serological-diagnosis-of-certain-human-animal-and-plant-diseases",bookSignature:"Moslih Al-Moslih",coverURL:"https://cdn.intechopen.com/books/images_new/1697.jpg",editedByType:"Edited by",editors:[{id:"112609",title:"Dr.",name:"Moslih",surname:"Al-Moslih",slug:"moslih-al-moslih",fullName:"Moslih Al-Moslih"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6470",title:"Rapid Test",subtitle:"Advances in Design, Format and Diagnostic Applications",isOpenForSubmission:!1,hash:"4511f4aaf7e54a38e8519d210290e032",slug:"rapid-test-advances-in-design-format-and-diagnostic-applications",bookSignature:"Laura Anfossi",coverURL:"https://cdn.intechopen.com/books/images_new/6470.jpg",editedByType:"Edited by",editors:[{id:"48947",title:"Dr.",name:"Laura",surname:"Anfossi",slug:"laura-anfossi",fullName:"Laura Anfossi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophile",surname:"Theophanides",slug:"theophile-theophanides",fullName:"Theophile Theophanides"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"314",title:"Regenerative Medicine and Tissue Engineering",subtitle:"Cells and Biomaterials",isOpenForSubmission:!1,hash:"bb67e80e480c86bb8315458012d65686",slug:"regenerative-medicine-and-tissue-engineering-cells-and-biomaterials",bookSignature:"Daniel Eberli",coverURL:"https://cdn.intechopen.com/books/images_new/314.jpg",editedByType:"Edited by",editors:[{id:"6495",title:"Dr.",name:"Daniel",surname:"Eberli",slug:"daniel-eberli",fullName:"Daniel Eberli"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1373",title:"Ionic Liquids",subtitle:"Applications and Perspectives",isOpenForSubmission:!1,hash:"5e9ae5ae9167cde4b344e499a792c41c",slug:"ionic-liquids-applications-and-perspectives",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/1373.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],ofsBooks:[]},correction:{item:{id:"74511",slug:"corrigendum-to-has-the-yield-curve-accurately-predicted-the-malaysian-economy-in-the-previous-two-de",title:"Corrigendum to: Has the Yield Curve Accurately Predicted the Malaysian Economy in the Previous Two Decades?",doi:null,correctionPDFUrl:"https://cdn.intechopen.com/pdfs/74511.pdf",downloadPdfUrl:"/chapter/pdf-download/74511",previewPdfUrl:"/chapter/pdf-preview/74511",totalDownloads:null,totalCrossrefCites:null,bibtexUrl:"/chapter/bibtex/74511",risUrl:"/chapter/ris/74511",chapter:{id:"72452",slug:"has-the-yield-curve-accurately-predicted-the-malaysian-economy-in-the-previous-two-decades-",signatures:"Maya Puspa Rahman",dateSubmitted:"December 9th 2019",dateReviewed:"March 21st 2020",datePrePublished:"June 11th 2020",datePublished:"December 23rd 2020",book:{id:"9534",title:"Banking and Finance",subtitle:null,fullTitle:"Banking and Finance",slug:"banking-and-finance",publishedDate:"December 23rd 2020",bookSignature:"Razali Haron, Maizaitulaidawati Md Husin and Michael Murg",coverURL:"https://cdn.intechopen.com/books/images_new/9534.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"206517",title:"Associate Prof.",name:"Razali",middleName:null,surname:"Haron",slug:"razali-haron",fullName:"Razali Haron"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"316535",title:"Associate Prof.",name:"Maya Puspa",middleName:null,surname:"Rahman",fullName:"Maya Puspa Rahman",slug:"maya-puspa-rahman",email:"mayapuspa@iium.edu.my",position:null,institution:null}]}},chapter:{id:"72452",slug:"has-the-yield-curve-accurately-predicted-the-malaysian-economy-in-the-previous-two-decades-",signatures:"Maya Puspa Rahman",dateSubmitted:"December 9th 2019",dateReviewed:"March 21st 2020",datePrePublished:"June 11th 2020",datePublished:"December 23rd 2020",book:{id:"9534",title:"Banking and Finance",subtitle:null,fullTitle:"Banking and Finance",slug:"banking-and-finance",publishedDate:"December 23rd 2020",bookSignature:"Razali Haron, Maizaitulaidawati Md Husin and Michael Murg",coverURL:"https://cdn.intechopen.com/books/images_new/9534.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"206517",title:"Associate Prof.",name:"Razali",middleName:null,surname:"Haron",slug:"razali-haron",fullName:"Razali Haron"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"316535",title:"Associate Prof.",name:"Maya Puspa",middleName:null,surname:"Rahman",fullName:"Maya Puspa Rahman",slug:"maya-puspa-rahman",email:"mayapuspa@iium.edu.my",position:null,institution:null}]},book:{id:"9534",title:"Banking and Finance",subtitle:null,fullTitle:"Banking and Finance",slug:"banking-and-finance",publishedDate:"December 23rd 2020",bookSignature:"Razali Haron, Maizaitulaidawati Md Husin and Michael Murg",coverURL:"https://cdn.intechopen.com/books/images_new/9534.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"206517",title:"Associate Prof.",name:"Razali",middleName:null,surname:"Haron",slug:"razali-haron",fullName:"Razali Haron"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},ofsBook:{item:{type:"book",id:"12173",leadTitle:null,title:"Dairy Processing - From Basics to Advances",subtitle:null,reviewType:"peer-reviewed",abstract:"
\r\n\tThe primary aim of this book is to integrate the knowledge of dairy product manufacturing with the chemistry of ingredients, along with the chemistry of several reactions which appear during the preparation of these products. Therefore, understanding the basic composition of milk and the chemistry of various constituents is of utmost importance. This will be the first topic that will be covered in this book, along with the advance and updated knowledge on the ingredients/ milk constituents. Over the years, the processing and manufacturing of several dairy products have witnessed upgraded processing equipment and hence the protocols of manufacturing. We also hope to cover the advanced processing methods for the production of dairy products.
\r\n\tFurthermore, during the preparation of high-quality dairy products, several physical, chemical, enzymatic, and microbial transformations take place. We will consciously focus on this interaction of different constituents of milk under different processing conditions for the development of the products.
Acromegaly is characterized by excess levels of insulin-like growth factor I (IGF-I) derived from autonomous growth hormone (GH) secretion from the pituitary somatotroph adenoma, which results in acral enlargement, coarse facial features, and visceromegaly [1, 2]. Even worse, acromegalic patients exhibit a shorter life span than healthy subjects owing to various comorbidities such as diabetes; hypertension; and cardiovascular, cerebrovascular, and respiratory diseases [1]. Malignant neoplasms in several organs including the thyroid, breast, prostate, pancreas, and digestive tract are also widely recognized as representative complications [1, 3, 4]. Even among those, patients with acromegaly are well known to have a significantly higher prevalence of colon neoplasms than the general population. Recent evidence suggests that even benign neoplasms such as adenoma and hyperplasia may have the potential to develop into malignant adenocarcinoma, which potentially affects the prognosis of acromegalic patients [5, 6, 7]. Recent guidelines recommend that while acromegalic patients are necessary to undergo colonoscopy regularly, they often face difficulties throughout colonoscopy intubation owing to distinctive features of acromegaly such as elongation of the colon [8]. Recently, the molecular mechanism behind colon tumorigenesis associated with the GH-IGF-I excess has been elucidated. In this chapter, we review the epidemiological evidence, protocol of follow-up colonoscopy, and underlying mechanism of GH/IGF-I-associated colon tumorigenesis in patients with acromegaly.
Klein et al. first demonstrated an increased prevalence of colon polyps in patients with acromegaly in 1982, reporting a prevalence of colorectal adenomatous polyps of approximately 30% in 17 patients with acromegaly [9]. Several subsequent reports also showed that colonic neoplasms were more frequently observed in 47% of patients with acromegaly, compared to the control with colonic lesions in 40% of asymptomatic males >50 years [10]. A cohort study identified 1041 male patients as having acromegaly from over 4 million men from the database of the United States Veterans Administration, which revealed a prevalence of acromegaly to be 277 cases/million [11]. In this study, 13 acromegalic patients had colonic cancer, which indicates a significantly higher prevalence than in the control group (SIR: 3.1; 95% CI 1.7–5.1) [11]. The UK registry of acromegaly diagnosed 16 patients as having colorectal cancer from a total of 1239 patients with acromegaly. Although this study did not show any significant change in the frequency of colorectal carcinoma compared to healthy subjects, the mortality rate of colon cancer was higher even though the overall mortality rate due to cancer was not increased [4]. An investigation of the incidence of cancer in 1643 hospitalized acromegalic patients in North Europe was performed, and the estimated standardized incidence ratio (SIR) was 2.6 (95% confidence interval [CI] 1.6–3.8) for overall colorectal cancer and 2.5 (95% CI 1.3–4.2) for rectal carcinoma [12]. Terzolo et al. performed colonoscopy to screen for colorectal tumors in 235 patients with acromegaly and compared the prevalence of colorectal tumors in this cohort with the prevalence in a control population who had no past and family history of colonic disease. Patients with acromegaly exhibited a higher prevalence of colon adenomas (acromegaly; 23.4% vs. control; 14.6%;
Thus, numerous studies documented evidence regarding risk of colorectal tumors in acromegalic patients, and several meta-analyses have demonstrated an increased prevalence of colorectal tumors including benign polyps and carcinomas. A German review meta-analyzed 9 eligible papers with strict inclusion criteria from 106 studies. As benign polyps, the pooled ORs with 95% CI of hyperplastic polyps and colon adenomas were 3.7 (95% CI; 2.6–5.3) and 2.5 (95% CI; 1.9–3.4), respectively. In terms of colon cancer, the pooled OR with 95% CI was 4.4 (1.5–12.4) [16]. The second study meta-analyzed 14 papers to determine the incidence of colorectal cancer [17]. After exclusion criteria was <10 expected cases, standardized incidence ratios (SIRs) were obtained from eight studies and the pooled SIR was 2.6 (95% CI; 1.7–4.0), which demonstrated an increased prevalence of colorectal cancer [18]. While the prevalence of colorectal cancer in female was significantly increased (SIR 1.86; 95% CI, 1.06–3.28
Although some studies described the frequency of colonoscopy for the follow-up in patients with acromegaly, there is still controversy on the appropriate follow-up [13, 19, 20]. The guidelines in 2002 recommended that colonoscopy should be performed every 3–5 years considering the past history of colon neoplasms and family history [21]. The next revision in 2009 suggested that colonoscopy should be performed at least once upon diagnosis in all patients with acromegaly. If colon polyps were detected in patients with acromegaly at the first screening, they should be carefully followed up based on the guidelines of screening and surveillance for general colorectal cancer [22, 23, 24]. However, several groups still appealed the importance of repeated colonoscopy on a regular basis for acromegalic patients [25, 26, 27]. Dworakowska et al. reported that patients who were diagnosed as having adenomatous polyp at first screening had a higher risk of developing a new lesion at the subsequent follow-up colonoscopy. Additionally, patients with poor IGF-I control had a 7.5-fold higher risk of a subsequent adenoma even if patients had a normal colon at the first screening [20].
The British Society of Gastroenterology and the Association of Coloproctology for Great Britain and Ireland in 2010 classified acromegalic patients as having a moderate to high risk of colorectal cancer on the update of the 2002 guidance, which suggested performing colonoscopy screening in those 40 years of age or older on a regular basis [28]. The frequency of repeat colonoscopy should be modified depending on the conditions of the initial screening and the activity of acromegaly. If the initial screening test showed negative results and IGF-I level was within normal range, the next colonoscopy will be scheduled 5–10 years later. When adenomatous polyps were detected at initial screening or higher IGF-I levels were noted, follow-up colonoscopy should be performed every 3 years [28]. The medical guidelines of the American Association of Clinical Endocrinologists (2011) and the Acromegaly Consensus Group (2013) state a similar recommendation that acromegalic patients should undergo initial colonoscopy at the time of diagnosis. If persistently elevated IGF-I level, abnormal findings by colonoscopy, or a family history of colon cancer is noted, follow-up colonoscopy should be performed more frequently. If not, a follow-up colonoscopy should be recommended every 10 years [29, 30].
Although current recommendations for surveillance colonoscopy in acromegaly may differ slightly among each study, collectively, it is deemed necessary to perform follow-up colonoscopy for cases with poor control of IGF-I and adenomatous polyps at least every 5 years according to five independent statements [20, 28, 29, 31]. Although an updated consensus from the Acromegaly Consensus Group in 2019 still recommends screening by colonoscopy at the time of diagnosis, they toned down the recommendation in terms of follow-up colonoscopy on a regular basis because there is no evidence linking screening frequency to colon cancer mortality rates [32, 33]. As acromegalic patients live longer than before owing to the improvement of biochemical control by advances in the treatment strategy, aging seems to be a more reliable indicator of cancer in patients with acromegaly than GH/IGF-I excess [34].
Secreted GH interacts with the GH receptor (GHR) that belongs to the class I cytokine receptor family, which is mainly expressed in the liver, fat, and muscle [35]. Consequently, phosphorylated GHR induces janus kinase 2 (JAK2) phosphorylation, which results in tyrosine phosphorylation of STAT5 (signal transducer and activator of transcription 5). STAT5 is the physiologically essential transcription factor for GH-dependent body growth, lipid metabolism, and sex-specific gene expression [36]. Recent studies have revealed that STAT5 plays an important role in tumorigenesis, especially cell proliferation and exertion of the anti-apoptotic property [37]. The phosphorylated STAT5 is associated with the development of malignant neoplasms including malignant prostate neoplasms, malignant breast neoplasms, and leukemia [37, 38, 39]. In colorectal cancer, the expression level of STAT5B is higher than in the normal colon tissue, and also correlates with the TNM stage [40]. Furthermore, phosphorylated STAT5 in colon adenocarcinomas is associated with a poor prognosis [41]. The phosphorylation of STAT5 is suppressed by suppressor of cytokine signaling-2 (SOCS2) in the GH signaling pathway [42]. A previous paper reported that SOCS2-knockout exhibited the development of hyperplastic mucosa and polyps in bovine GH-transgenic mice [43] Furthermore, d3GHR polymorphism caused the signaling enhancement, which resulted in increasing the risk of colon adenoma regardless of circulating IGF-I concentration compared to intact GHR in acromegalic patients [44]. Recently, we reported that the GH area under the curve in the oral glucose tolerance test exhibited higher prevalence in colon cancer patients than in colonic benign tumor patients [15]. These data suggest the significance of excessive GH signaling in the development of epithelium-adenoma-carcinoma, independent of IGF-I signaling [45].
Bowel enlargement in acromegalic patients is observed associated with accumulative excessive GH and IGF-I [46, 47, 48]. Enhanced proliferation of colonic epithelial cells and reduced apoptosis of the colonic mucosa were observed in patients with acromegaly [47, 49]. Interestingly, an increased proliferation rate of colonic epithelium cells was correlated with circulating IGF1 levels [50]. IGF-I receptor knockout mice exhibited a decreased cell proliferation and increased apoptosis [1]. The IGF-I/IGF-IR system also plays an important role in the promotion of cell adhesion, migration, and tumor microenvironment including the angiogenesis in the tumor [51]. The IGF-IR mRNA expression level in the colon cancer tissue was associated with paracrine/autocrine effects [1]. Even in those with normal IGF-I levels, there was a positive association between circulating IGF-I levels and the risk of colorectal cancer in a meta-analysis of 19 epidemiological studies [52]. However, several previous studies suggested that the classification based on the type of colorectal neoplasms or with/without colorectal neoplasms did not correlate with serum IGF-I levels [13, 15, 53, 54]. Taken together, elevated levels of serum IGF-I may also involve colorectal tumorigenesis, but it still needs further investigation.
In terms of direct action of GH as a novel insight, it has recently been reported that locally expressed GH in the colon is a precursor to colon cancer. Excessive GH leads to cell survival with downregulation of tumor suppressor genes such as p53 and APC, which results in neoplastic colon growth [55]. GH suppressed DNA damage response (DDR) by inhibiting phosphorylated ataxia telangiectasia mutated (ATM), checkpoint kinase 2 (Chk2), and p53. They also elucidated that GH significantly increased unrepaired DNA damage in colon epithelial cells, and colon cancer cell lines of xenografted mice with GH overexpression exhibited more metastases compared to colon cancer cell lines of control mice [56], and these mechanisms were observed independent of IGF-I action [57].
As mentioned above, various mechanisms are involved in tumorigenesis of colorectal neoplasms. These mechanisms can account for the tumorigenesis of colorectal adenomatous polyps or adenocarcinomas, but not hyperplastic polyps. As a noteworthy fact, hyperplastic polyps are basically considered as benign neoplasms, while colorectal adenoma is widely recognized as pre-malignant conditions based on the presence of the adenoma-carcinoma sequence. Indeed, hyperplastic polyps are described by a superficial serrated architecture and variably elongated crypts with proliferation confined to the lower portion of the crypt [58]. However,
Colorectal neoplasm, especially adenocarcinoma, is a life-threatening comorbidity of acromegaly. Accumulating data clearly demonstrate the increased prevalence of colorectal polyps and cancer in patients with acromegaly even among different races and countries. Although the appropriate follow-up protocol of colonoscopy remains controversial, different guidelines state that cases with poor control IGF-I and adenomatous polyps should be classified as having a high risk of colon cancer. In terms of molecular mechanisms, both GH and IGF-I are implicated in colon cancer development.
There is no universally accepted definition of ischemic cardiomyopathy (ICM). However, the term ischemic cardiomyopathy generally refers to significantly impaired left ventricular function (left ventricular ejection fraction [LVEF] ≤35–40%) that results from coronary artery disease (CAD) [1, 2, 3]. In 2002, Felker et al. suggested that the symptomatic patients with LVEF ≤40% and presence of left main or proximal left anterior descending coronary artery stenosis ≥75% or two or more epicardial coronary artery stenosis ≥75% or a prior history of coronary artery revascularization [percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)] or prior history of myocardial infarction should only be classified as having ICM [3].
Ischemic heart disease is a global pandemic, and its incidence continues to increase. In an estimate, 125 million people across the globe suffer from ischemic heart disease. In the United States itself, every year 720,000 people develop their first myocardial infarction (MI) resulting in hospitalization and/or death [4, 5]. Thirty-five percent of the patients who experience coronary event in a given year die due to it; and each death is associated with an average of 16 years of lost life. Patients who survive after the myocardial infarction are at an increased risk of developing ICM and eventually heart failure (HF). Etiopathogenesis of heart failure is multifactorial; however, ischemic cardiomyopathy is the single most common cause of heart failure. More than 64.3 million people across the world and 6 million people in the United States currently experience HF [3, 6]. In addition to increase in human toll, the estimated cost of HF exceeds $60 billion each year [7, 8].
In patients with coronary artery disease, rupture of atherosclerotic plaque followed by in situ thrombus formation leads to sudden cessation of coronary blood flow. If the coronary blood flow is not established early enough either by spontaneous, pharmacological, or interventional recanalization, the death of ischemic myocytes ensues. With time, dead myocytes are replaced with fibrous tissue. Once the amount of scarred myocardium is significant enough after single or multiple episodes of MI, the left ventricle remodels with dilatation, regional deformation, and decrease in overall contractility. Remodeling and alteration of LV geometry especially the inferior wall may also lead to papillary muscle malalignment and mitral regurgitation (MR). Left ventricle volume overloading due to chronic MR in association with poor left ventricular contractility sets up a vicious cycle of worsening LV remodeling and MR [9].
The replacement of the dead myocardium with fibrous tissue is the most important mechanism in the development of ICM. Other pathophysiological processes such as myocardial stunning and hibernation that render the viable myocardial cells unable to perform their mechanical work and also contribute to the development of ICM. Both myocardial stunning and hibernation are reversible forms of myocardial contractile dysfunction that have the potential of mechanical work restoration if the blood flow supply can be improved [10]. In any given heart with ICM, all three stages of myocardium, i.e., normal, viable but hypocontractile and scarred myocardium often coexist within a single cross section of LV. Thus, ischemic cardiomyopathy is extremely heterogeneous and particularly challenging for accurate viability assessment with imaging studies [11].
The concept of hibernating myocardium is interesting as well as mysterious. Our present understanding about the hibernating myocardium is limited [12, 13, 14, 15, 16]. Rahimtoola [17] described the hibernating myocardium as “resting left ventricular dysfunction due to reduced coronary blood flow that can be partially or completely reversed by myocardial revascularization and/or by reducing myocardial oxygen demand.” Hibernating myocardium is usually limited to subendocardial tissues. Histologically, in hibernating myocardium, there is loss of contractile proteins and sarcoplasmic reticulum without the change in the cell volume. Presumably, hibernation is a protective dedifferentiation of myocardial cells or switch to a quiescent state of decreased mechanical work in times of chronically decreased oxygen supply [13]. This adaptive mechanism probably allows the myocytes to avoid the ischemic imbalance and remain alive in the milieu of decreased coronary blood flow that would otherwise lead to cell death. Alternative mechanism for ventricular dysfunction in ICM may be myocardial stunning. Myocardial stunning apparently occurs due to repeated episodes of ischemic insult that result in viable but chronically hypocontractile myocardium (i.e., repetitive stunning). Due to extremely low ischemic threshold of the myocytes, any decrease in coronary blood flow during stress leads to ischemia and ischemia–reperfusion changes in the myocytes despite normal or insignificantly decreased resting coronary perfusion [13, 18]. This repetitive stunning of the myocytes results in chronic LV dysfunction. Thus, in patients with ICM, territories with high numbers of cardiomyocytes with excess glycogen reserve and less fibrosis in all probabilities are reversible after revascularization. These myocytes also demonstrate higher blood flow and glucose uptake on positron emission tomography (PET) scan [19].
Patients with ICM present with myriad of signs and symptoms depending upon the severity of heart failure and degree of physiological compensation. Some patients may be asymptomatic or minimally symptomatic with mild anginal chest pain and dyspnea on exertion while other patients may present with overt heart failure symptoms, e.g., dyspnea, orthopnea, poor exercise tolerance, and increased fatigability. Patients usually have a longstanding history of coronary artery disease and a prior history of myocardial infarctions. Physical examination can reveal bibasilar crackles, S3 gallop, displaced apical impulse, carotid bruits, jugular venous distension, positive hepato-jugular reflex, and bilateral lower extremity edema.
In patients with ICM, multivessel disease, low LVEF, and increased LV end-systolic volumes are important prognostic factors. Therefore, all these factors must be taken into consideration when making the difficult decision regarding revascularization. Suitability of the patient for CABG depends upon: A) suitability of the diseased coronary arteries for bypass grafting; B) the amount of viable myocardium present and whether the viable myocardium is present in the territory of CAD; C) severity of right and left heart failure; and D) associated cardiac lesions. All the diagnostic investigations should be directed toward determining whether the patient is a suitable candidate for CABG or not.
Transthoracic echocardiography (TTE): Transthoracic echocardiography is an essential investigation in assessing myocardial viability in a patient with ICM. Echocardiography is useful in evaluating cardiac anatomy, valvular function, ventricular systolic/diastolic function, cardiac wall motion, and pericardial pathology. All this information is useful in diagnosing ischemic cardiomyopathy, especially in patients with HF and other high-risk features.
Coronary angiography: Coronary angiography allows direct visualization of the coronary arteries for assessment of severity of obstruction, collateralization, and the blood flow to the myocardium. Coronary angiography is most important in defining the extent and severity of coronary artery disease and whether the coronaries arteries are suitable for grafting. Computed tomography coronary angiography can also be performed in place of conventional coronary angiography to assess coronary arteries in patients with low to intermediate risk of CAD [20].
Cardiac stress test: There are different stress tests available depending on the patient’s health, functional status, baseline heart rhythm, and exercise tolerance. The goal of these stress tests is to assess for cardiac ischemia and myocardial viability. Late gadolinium enhancement cardiac magnetic resonance (LGE-CMR), dobutamine stress echocardiography, single-photon emission computed tomography (SPECT), and F-18- fluorodeoxyglucose positron emission tomography (FDG-PET) imaging can be used to assess myocardial viability [21]. Dobutamine stress echocardiography is widely used to assess myocardial contractility reserve and viability. With continuous dobutamine infusion, initially myocardial perfusion increases along with increased contractility. However, as the dobutamine dose increases, blood flow cannot be escalated further leading to reduced myocardial contractility. This phenomenon known as biphasic reaction can predict the recovery of the myocardial function after revascularization.
Late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) can detect increase in extracellular space due to myocardial apoptosis and necrosis and can predict the reversibility of the myocardial contractility after successful revascularization while dobutamine stress CMR can detect the ischemic myocardium. In patients with ICM with transmural infarct, minimal LGE (<25%) in dysfunctional myocardial segment indicates a high likelihood of recovery while the chance of recovery is minimal in segments with >50% LGE.13 In segments with 25–50% LGE involvement, the recovery prediction is not consistent [22].
Single-photon emission computed tomography (SPECT) and positron emission tomography (PET) had been widely utilized in the past to assess myocardial viability. Thallium-based SPECT scan demonstrate delayed distribution but has increased risk of ionizing radiations while technetium-based SPECT has less risk of radiation, but it cannot demonstrate a delayed distribution. Another nuclear imaging modality to assess myocardial viability is cardiac PET. PET imaging is based on the principle that in an ICM, ischemic myocardium switches to glucose-based metabolism instead of fatty acids. 18F-fluorodeoxyglucose (18F-FDG) can detect this shift in viable but ischemic myocardium. PET has higher spatial resolution, lower risk of radiation, and better attenuation correction compared with SPECT. PET, however, cannot distinguish between normal and ischemic or hibernating myocardium in patients with insulin resistance, and results may be inaccurate in patients with variable uptake of FDG due to heart failure [23].
Brain natriuretic peptide (BNP) test: BNP is synthesized in the ventricles, and it is secreted when the myocardial muscle has a high wall tension. BNP is an important biomarker for heart failure patients. Increasing trend in BNP suggests worsening of heart failure; however, it cannot detect myocardial ischemia.
Coronary artery bypass grafting for CAD started in the mid-1960s. Since then, numerous clinical trials and studies have tried to address different questions related to the management of CAD. All these trials and studies have established an undisputed role of surgical revascularization in patients with CAD in terms of improved survival, risk of reintervention, and quality of life [24, 25, 26, 27]. Nevertheless, prior to Surgical Treatment for Ischemic Heart Failure (STICH) trial [28], none of the studies specifically addressed the management of patients with ICM. The coronary artery surgery study (CASS) trial registry that followed the patients who were excluded from the main study reported that patients with LVEF <35% had better survival with CABG than with medical therapy, if they had associated three-vessel disease and if the presenting symptom was angina [29]. Similarly, a 25-year observational study involving 1391 patients (medical therapy (n = 1052) or CABG (n = 339)) from Duke Cardiovascular Disease Databank also reported an improved survival with CABG over medical therapy alone after 30 days to more than 10 years in patients with NYHA class ≥II, CAD with at least one vessel stenosis ≥75%, and LVEF <40%. The benefit with CABG was observed irrespective of the extent of coronary artery involvement (P < 0.001) [30].
These observational studies pointed toward the role of CABG in patients with ischemic cardiomyopathy; however, lack of randomized clinical studies in patients with ICM led to different therapeutic approaches driven by the physician bias regarding the potential benefit of myocardial revascularization [9]. The resulting equipoise formed the basis for the multiinstitutional STICH randomized controlled clinical trial [28]. STICH trial was the first and only large-scale randomized clinical trial to compare surgical revascularization with medical therapy in patients with LVEF ≤35% and CAD amenable to CABG. The STICH trial randomly assigned 1212 patients to three groups (medical therapy alone, medical therapy with CABG, and medical therapy with CABG and SVR). To evaluate the superiority of either procedure, two hypotheses were developed. In Hypotheses 1, the investigators evaluated medical therapy against medical therapy with CABG. All patients underwent coronary angiography to define the extent of CAD; patients with critical left main disease or unstable coronary syndromes were excluded from the trial. The primary outcome of the study was all-cause mortality, and secondary outcomes were cardiovascular mortality, combination of all-cause mortality and hospitalization for cardiac causes. At a median follow-up of 56 months, medical therapy plus CABG surgery resulted in a nonsignificant trend toward improvement in the primary outcome (36% vs. 41% with medical therapy alone) as well as significantly lower cardiovascular mortality and improved quality of life (at 4, 12, 24, and 36 months as assessed by the Kansas City Cardiomyopathy Questionnaire) [31]. However, this trial was fraught with certain limitations. First, during the study period, 9% patients in medical therapy plus CABG group crossed over to medical therapy group only while 17% patients in medical therapy alone group crossed over to medical therapy and CABG group. This crossover may have led to a diminished treatment benefit, thereby preventing the primary outcome from reaching statistical significance. Second, the STICH trial was designed to maximize both medical and surgical outcomes using strict criteria for surgical expertise (e.g., documented surgical expertise by volume and outcome criteria) and regular review of both surgical center conduct and intensity of medical therapy. Clinical equipoise had to be present, and both the surgeon and cardiologist had to believe revascularization was technically feasible. Both these issues may limit the generalizability of the trial to routine clinical practice.
In 2016, results of extended follow-up of STICH trial patients, i.e., the STICH Extension Study (STICHES), were published extending the median follow-up to 9.8 years [32]. After 9.8 years, the primary outcome (all-cause mortality) was significantly lower in the medical therapy and CABG group compared with medical therapy alone group (59% vs. 66%; hazard ratio [HR] 0.84; 95% CI, 0.73–0.97). Medical therapy and CABG group also experienced significant reductions in cardiovascular mortality (40.5% vs. 49.3%; HR 0.79; 95% CI, 0.66–0.93) and the combination of all-cause mortality and cardiovascular hospitalization (76.6% vs. 87%; HR 0.72; 95% CI, 0.64–0.82). Another large population based observational study related to CAD with LV systolic dysfunction was reported [33], it is recommended to do CABG and medical therapy for patients with ICM who have coronaries amenable to surgical revascularization.
Observational studies done in early 2000s focused on the potential benefit of viable myocardium on the patient survival and LV function after the revascularization. Initial potential survival benefit from revascularization in patients with ICM and viable myocardium was reported in a meta-analysis published in 2002. This meta-analysis included 24 nonrandomized viability studies involving 3088 patients with CAD and LV dysfunction who had a mean LVEF of 32% [34]. Patients with myocardial viability had 80% reduction in annual mortality with revascularization (3.2% vs. 16% with medical therapy alone), while there was no significant change in annual mortality with revascularization in patients without myocardial viability (7.7% vs. 6.2% with medical therapy alone). Potential effect of viable myocardium on LVEF was also illustrated in a review published in 2004 that involved 29 observational studies including 758 patients [35]. In this review, LVEF increased after revascularization when myocardial viability was present (37–45%) but did not change significantly in the absence of viability. Further, studies have also demonstrated that 25–30% of the dysfunctional myocardium needs to be viable to result in improvement of LVEF. On the contrary, in a substudy of the STICH trial, 601 of the 1212 patients were evaluated for myocardial viability, and outcomes were analyzed according to those assigned to receive medical therapy plus CABG or medical therapy alone. Study showed minimal improvement in LVEF with revascularization (from 28% pre-CABG to 30% post-CABG). Following adjustment for differences in baseline variables and with follow-up extending beyond 10 years, there was no significant improvement in mortality with medical therapy plus CABG compared with medical therapy alone. Myocardial viability was associated with reduced mortality but did not predict a benefit from revascularization. This raises the question of whether viability assessment is needed prior to surgical revascularization. However, myocardial viability in STICH trial was assessed using stress echocardiography and SPECT radionuclide myocardial perfusion imaging; more contemporary techniques such as CMR and positron emission tomography (PET) were not studied and are an important limitation of the STICH findings [36]. Presence of myocardial viability does lead to improvement in contractility and myocardial thickness following revascularization subject to the presence of at least 25–30% of viable myocardium and scar burden <25% (as detected by LGE-CMR) [37]. However, inconsistencies in the criteria and the methods used to diagnose myocardial viability between various studies have led to blurring of the evidence of benefit of revascularization.
In the absence of firm evidence, routine viability assessment prior to consideration for CABG in patients with ICM is not recommended. However, situations that require greater precision in defining large infarcts either due to associated excessive surgical morbidity (e.g., renal failure) or risk of suboptimal outcome (e.g., evidence of LV remodeling, inability to achieve complete revascularization); viability assessment with more contemporary techniques such as LGE-CMR or FDG-PET may help further refine the potential risks and benefits.
Left ventricular size is an important determinant of outcome after surgical revascularization in patients with ICM. However, our present understanding of impact of preoperative LV size on postoperative LV function and survival is still limited. The impact of left ventricular enlargement on the improvement in LV function after revascularization was illustrated in a review of 61 patients with ischemic heart disease and a mean LVEF of 28%, all of whom had an evidence of substantial myocardial viability [38]. One-third of the patients had no significant improvement in the LVEF (≥5%). The study showed that the patients with a significant improvement in LVEF after CABG had a significantly smaller left ventricular end-systolic volume (LVESV) on preoperative echocardiography than those without improvement (121 mL vs. 153 mL). The observational data are in contrast with the findings from the STICH trial, which found greater benefit with respect to mortality in patients with greater baseline remodeling (e.g., larger left ventricle end-systolic volume index [LVESVI]) [28].
Percutaneous coronary intervention (PCI) is an established treatment for revascularization in acute myocardial infarction. Role of PCI in management of ICM is still unclear due to the lack of well-designed randomized studies. In the lack of randomized controlled study, best available data come from the observational study comparing PCI with CABG in 4616 patients with LVEF ≤35% who were enrolled in New York State registries (1351 underwent PCI with drug eluting stents and 3265 underwent CABG), from which 2126 patients were chosen for evaluation based on propensity score matching [39]. At a median follow-up of 2.9 years, there was no significant difference in mortality between contemporary PCI and CABG (HR 1.01; 95% CI 0.81–1.28). PCI was associated with a greater risk of myocardial infarction (HR 2.16; 95% CI 1.42–3.28) and need for repeat revascularization (HR 2.54; 95% CI 1.88–3.44), but a significantly lower risk of stroke compared with CABG (HR 0.57; 95% CI 0.33–0.97).
In a separate post hoc analysis of AWESOME trial, in which 454 patients who had medically refractory unstable or provocable ischemia were randomized to PCI or CABG. Ninety-four patients had LVEF <35% (mean 25%) [40]. Among patients with LVEF <35%, there was no difference in mortality between CABG and PCI. However, limitation of this trial was that all patients included in the study had angina and acute coronary syndromes and not heart failure.
The mechanism of survival advantage conferred by CABG in patients with heart failure irrespective of myocardial viability still remains speculative, although, post hoc analysis of STICH trial has been able to shed some interesting insight on this topic. In STICH trial, a subanalysis evaluating cause-specific cardiac mortality in patients with ICM demonstrated that sudden cardiac death (SCD) was the most frequent mode of death and outnumbered pump failure deaths by approximately twofold [41]. Further, both SCD and death from HF were significantly reduced after the CABG (as was death from myocardial infarction). Predictors of increased risk of SCD in this analysis were increased LVESVI and elevated BNP level. Interestingly, same variables along with regional myocardial sympathetic denervation were found to be significant risk factors for SCD in patients with ICM in the Prediction of Arrhythmic Events with Positron Emission Tomography (PAREPET) Study [42, 43]. Thus, the survival benefit of CABG in patients with ICM is largely due to the significant effect of revascularization on reducing the death due to arrhythmia with a smaller contribution from reducing the deaths from pump failure and fatal MI.
We suggest the combined CABG and medical therapy instead of medical therapy alone for patients with ICM and CAD that is amenable to surgical revascularization. This suggestion is based primarily on a 7% absolute reduction in overall mortality over 10 years (STICH trial) and superior relief of anginal symptoms following CABG. However, as significant morbidity and early mortality (compared with medical management alone) are associated with CABG in patients with ICM, patients may also reasonably choose medical therapy alone as the initial treatment option. Following initiation of medical therapy, patients should be reevaluated on an ongoing basis for any changes in clinical status or symptoms and consideration for surgical revascularization should be discussed with the patient.
Other clinical features that should be considered while tailoring the decision for any given patient are greater functional capacity (6-minute walk >300 m), greater burden of CAD (e.g., three-vessel disease), coexistent moderate to severe mitral regurgitation (MR), lower ejection fraction (e.g., LVEF <35%), and greater remodeling (e.g., LVESVI >79 mL/m2) (associated with improved outcomes in STICH trial).
Additionally, we do not recommend routine viability assessment prior to consideration for surgical revascularization and consideration should be case-to-case basis especially in patients in whom the risk-to-benefit profile is not as clear (e.g., patients with significantly elevated surgical risk). We believe that viability study may not aid in decision-making; however, the presence of significant viability and < 25–30% scar on LGE-CMR gives reassurance to the surgeon for improved surgical outcome.
Considering the advantage with CABG from the STICHES trial, it seems that patients with suitable targets for revascularization in the setting of an EF < 35% with two or three vessel CAD should be considered for CABG irrespective of the results of viability testing. However, competing risk factors such as severity of heart failure, age of the patient, and risks for noncardiac mortality need to be carefully weighed in considering the recommendation for revascularization and decision should be made on individual basis.
Factors that have been consistently associated with adverse outcomes after CABG for patients with ICM include preoperative renal dysfunction, advanced HF, recent myocardial infarction, and hemodynamic instability. Perioperative shock in this patient population more than doubles the rate of perioperative mortality [44, 45, 46]. Therefore, preoperative optimization of the patient status can improve the patient outcome after the surgery. The specific mode of optimization should be individualized to patients’ needs and driven by their response to initial therapy. If medical therapy alone is ineffective, more invasive measures should be considered. In the preoperative setting, prophylactic intra-aortic balloon pump (IABP) decreases afterload, increases coronary artery perfusion, provides a modest increase in cardiac output [47, 48]. In a variety of analyses, IABP therapy before the operation has been noted to result not only in improved patient condition before CABG, but also in reduced perioperative morbidity and mortality. Two meta-analyses of randomized clinical trials examining the utility of preoperative IABP therapy in patients with ICM demonstrated a strong association between preoperative use of IABP and reduced hospital mortality, lower incidence of low cardiac output syndrome, and shorter duration of ICU stay. Patients with high-risk profile including low LVEF, left main disease >70%, prior heart surgery, poor coronary artery targets, and unstable angina typically benefit from preoperative IABP [47, 48, 49, 50].
In patients who present with cardiogenic shock resulting from acute myocardial infarction or decompensated HF with end-organ dysfunction, IABP may be inadequate for stabilization or preoperative optimization. In these patients, transvalvular devices such as microaxial surgical heart pump can be used. These devices reduce left ventricular end-diastolic pressure (LVEDP) and volume workload and provide the circulatory support necessary to allow native heart recovery. In a recent analysis, the use of these micro-axial pump was associated with reduced mortality, without significant increase in device-related stroke, hemolysis, or limb ischemia [51, 52]. Finally, in patients with cardiogenic shock that is refractory to inotropic support, IABP, and/or microaxial pumps, ventricular assist device (VAD) implantation should be considered [47, 53, 54].
Patients with ICM with cardiogenic shock, who have organ dysfunction at the time of presentation, temporary VAD can be used as bridge to decision. Patients who reverse their organ dysfunction and acidosis after the insertion of temporary MCS and demonstrate an adequate contractile reserve and response to inotropic stimulation can successfully bridge to CABG. This is contingent to good coronary targets and absence of unfavorable anatomic and physiologic profiles [27]. Otherwise, they should be evaluated for heart transplant and should be considered for more durable VAD option as bridge to transplant.
The goal of CABG in patients with ICM is to achieve expeditious and complete revascularization. On-pump arrested-heart CABG is the most commonly used strategy that allows a bloodless and still field that facilitates complete revascularization [55]. Excellent myocardial protection especially right ventricle is paramount in the setting of ischemic cardiomyopathy as myocardial ischemia and injury are poorly tolerated when myocardial reserve is limited [56].
In patients undergoing on-pump CABG, controversy still remains about type of cardioplegic solution, temperature, and route of administration that provides the optimal myocardial protection. This becomes critical in patients with ICM as any amount of further myocardial damage may be deleterious. In a meta-analysis of 12 studies including 2866 patients, lower prevalence of perioperative myocardial infarction was found in patients who received blood cardioplegia [57]. Another meta-analysis of 41 randomized clinical trials (RCT) found that warm cardioplegia did not improve clinical outcomes but was associated with a mild reduction of cardiac enzyme release [58]. Single-dose cardioplegia benefit is limited to a reduction in ischemia and bypass time and does not translate into a major morbidity or mortality advantage [59]. There is no systematic comparison of different routes of cardioplegia administration (i.e., antegrade vs. retrograde vs. combined); however, isolated retrograde cardioplegia should be avoided due to its heterogeneous perfusion and unpredictable right ventricle myocardial protection [60]. On the other hand, retrograde cardioplegia may be useful in adjunct to antegrade cardioplegia in patients with severe CAD and in redo CABG to reach territories not otherwise reachable by antegrade delivery and to flush potential embolic debris from inadvertently manipulated diseased vein grafts [61, 62]. Although data are scarce, it has been reported that antegrade cardioplegia supplemented with venous graft perfusion can significantly improve myocardial protection. The most suitable myocardial protection strategy may be a combination of antegrade, retrograde, and delivery down the vein grafts.
Utilization of off-pump CABG (OPCABG) is limited to few centers and selected patients in the developed countries. There have been no large RCTs comparing on-pump CABG versus OPCABG and small RCTs that did compare these two modalities have reported inferior or non-superior long-term outcome with OPCABG. Most of these studies are limited by smaller sample size, short duration of follow-up, and limited experience of the operator. This is of particular relevance given that OPCABG may lead to inferior long-term outcomes if performed by inexperienced operators and/or accompanied by incomplete revascularization [63]. In a meta-analysis of 23 individual nonrandomized studies published in 2011 that involved 7759 CABG patients with LVEF <40%, 2822 patients underwent OPCABG. Overall early mortality was significantly reduced (odds ratio [OR], 0.64; 95% CI, 0.51–0.81) in OPCABG group. Similar results were observed on subgroup analysis of 1915 patients with LVEF <30% (OR 0.61; 95% CI 0.47–0.80) [64]. A recent meta-analysis published in 2020 comprising 16 studies with 32,354 patients with LV dysfunction (defined as LVEF <40%) also reported a significant reduction in 30-day mortality (OR 0.84; 95% CI 0.73–0.97), perioperative complications, and transfusion requirements with OPCABG [65]. In a report published in 2016 from the Japan Adult Cardiovascular Surgery Database including 918 pairs of propensity-matched CABG patients with LVEF <30%, there was reduced perioperative and 30-day mortality with OPCABG (1.7% vs. 3.7%; P < 0.01) and reduced incidence of mediastinitis, reoperation for bleeding, and need for prolonged ventilation, but there was no difference in incidence of stroke or renal failure compared to on-pump CABG [66].
On-pump beating-heart CABG has been proposed as an alternative strategy to on-pump cardioplegic arrest CABG, particularly in higher-risk patients including patients with impaired LV function [67]. This technique is more of historical significance as it is rarely used nowadays. In a review of 11 studies, comprising two RCTs and nine observational studies comparing on-pump beating-heart CABG and on-pump arrested heart CABG, lower mortality was reported with on-pump beating-heart CABG in five of the nine observational studies while mortality was similar with both techniques in two RCTs. However, due to the lack of randomization and the absence of propensity matching, the possibility of selection bias accounting for the difference in mortality cannot be discounted. Intraoperative myocardial injury with on-pump beating heart may increase due to inadequate coronary perfusion distal to areas of stenosis [68].
In the absence of more definitive evidence about the superiority of one technique of CABG over the other, the operative strategy should be tailored based on patient factors such as extent of CAD and associated comorbidities, surgeon’s expertise and comfort level of the cardiac anesthetist, and center experience. When off-pump technique is used, maintenance of appropriate perfusion pressure and when on-pump CABG is utilized, appropriate myocardial protection is imperative to minimize further myocardial injury.
Presently, use of left internal mammary artery (LIMA) for bypassing left anterior descending coronary artery and reverse saphenous vein grafts for bypassing rest of the coronary arteries is the standard of care across the globe. Evidence from the recent studies has shown the superiority of multi-arterial grafting in improving long-term patient survival after CABG. The impact on survival becomes even more significant with increasing duration of follow-up [69, 70, 71]. The evidence of beneficial effects of multi-arterial grafting in patients with ICM, however, is limited to few studies and a small number of patients [72, 73, 74]. Further, multi-arterial grafting in patients with ICM still remains controversial as the overriding priority in these patients is to mitigate the upfront risk of surgery and avoidance of perioperative myocardial ischemia. In a risk predictive model based on STS database review of patients operated for CABG, the HR for perioperative mortality after isolated CABG was 1.19 (95% CI, 1.17–1.22) for every 10% reduction in LVEF [75], and operative risk was further compounded with the addition of noncardiac organ dysfunction and other comorbidities.
There are four reasons why caution should be used when contemplating multi-arterial grafting in patients with ICM [56]. First, perioperative administration of high doses of vasopressors may be necessary in these patients, and this is an important predisposing factor for the development of spasm in the arterial grafts [76]. Radial and gastroepiploic arteries are particularly vulnerable to spasm compared with IMAs. Second, adequacy of blood flow in a fresh arterial graft may not be as robust as in a vein graft, with the potential for clinically significant perioperative coronary artery hypoperfusion [77, 78, 79]. Third, multi-arterial grafting usually adds to the complexity and length of the operation and prolongs myocardial ischemic time. This may not be well tolerated by the patients with ICM. Fourth, arterial grafts may not be of adequate length in massively dilated hearts, especially if sequential anastomoses are contemplated. A patient-level combined analysis of six RCTs associated radial artery grafts in addition to LIMA with improved clinical outcomes compared with venous grafts [80]. The benefit of radial artery grafting was persistent even on subgroup analysis of patients with severe LV dysfunction (LVEF <35%). However, the number of patients in subgroup were limited (25 (4.7%) and 32 (6.4%) in the radial artery and saphenous vein groups, respectively). The results of other observational studies have yielded mixed results with the use of multi-arterial grafting in patients with ICM [73, 81, 82, 83, 84]. The probable reason is variable cutoff for LVEF with different studies (lowest limit <30%), which adds to uncertainty regarding multi-arterial grafting benefits [85]. Observational evidence also suggests that the benefit of multi-arterial grafting is lost in patients with ICM with limited life expectancy or severe associated comorbidities [83, 86, 87, 88].
We believe that multi-arterial grafting should not be routinely recommended for patients with ICM. Patient selection for multi-arterial grafting should be based on patient factors and surgeon’s experience and comfort. Young patients with compensated HF having good target for bypass may be considered for multi-arterial grafting if the risk–benefit ratio is favorable and prolonged survival is anticipated after revascularization.
Atrial fibrillation (AFib) is present in 5–10% of patients undergoing CABG. It is associated with increased risk of complications including stroke and renal failure, prolonged hospital stay as well as increased mortality despite adjustment for potential confounders [89]. Therefore, current North American and European guidelines for CABG recommend concomitant AFib ablation procedure in symptomatic patients or asymptomatic patients having low operative risk [90, 91]. The evidence supporting the surgical ablation of AFib in patients with ICM undergoing CABG is minimal and limited by selection bias [92]. Theoretically, patients with a reduced ejection fraction would benefit from the restoration of sinus rhythm and atrial contraction [93]. However, concomitant AFib ablation procedure adds to the technical complexity of the surgery and prolongs the duration of aortic cross clamp and cardiopulmonary bypass. Despite this, some studies reported that surgical AFib ablation is safe and effective in patients with heart failure [94, 95].
Up to 10% patients develop chronic moderate or severe MR following acute myocardial infarction. Chronic ischemic mitral regurgitation (CIMR) is associated with an increased incidence of heart failure and increased risk of mortality in patients with LV dysfunction [96]. Furthermore, LV dysfunction can lead to gradual dilatation and geometric change in the left ventricle that results in distortion of the mitral valve and worsening of MR. Although, there is a general consensus to repair or replace the mitral valve in patients with severe CIMR undergoing CABG, the management of moderate (Grade II) mitral regurgitation still remains controversial.
In the Cardiothoracic Surgical Trials Network study, adding surgical mitral valve repair to CABG in patients with moderate CIMR had no significant effect on survival or LV reverse remodeling at 2 years follow-up but was associated with increased duration of hospital stay and morbidity including neurological events and atrial arrhythmias [97]. Smaller RCTs have shown benefit in surrogate outcomes for CABG and mitral valve repair versus CABG alone in patients with moderate CIMR [98, 99]. However, none of the trials has specifically focused on patients with ICM. In patients with severe CIMR, mitral valve replacement has been shown to provide more reliable and durable relief of MR than repair, but without survival benefit [100]. Mitral valve replacement rather than repair is also favored in patients with LV basal aneurysm/dyskinesis or other potential risk factors for recurrent MR after repair, e.g., significant leaflet tethering and/or severe left ventricular dilatation (LV end-diastolic dimension >6.5 cm). Preserving the subvalvular apparatus is also strongly recommended when replacing mitral valve in these patients. Concerns about persistent tethering of the posterior leaflet and recurrent MR after CABG in patients with prior inferior wall MI have prompted some to combine mitral anuloplasty with a subvalvular procedure such as papillary muscle approximation and papillary muscle relocation. All these procedures result in improved echocardiographic and cardiovascular outcomes but fail to influence all-cause mortality or quality of life [101, 102, 103]. Therefore, this remains an area for further study and evaluation.
Tricuspid regurgitation (TR) is an established risk factor in patients undergoing CABG [104]. In patients with CIMR, although progression of unrepaired mild to moderate TR after revascularization is uncommon, presence and progression of moderate or greater TR are associated with increased incidence of clinical events [105]. The underlying etiology of TR in ICM includes tricuspid annular dilatation and leaflet tethering in the setting of RV remodeling due to right ventricle infarction with or without pulmonary hypertension, tricuspid annular dilatation associated with AFib, and iatrogenic or lead related injury to tricuspid leaflets. Current AHA/ACC guidelines assign class I recommendation for tricuspid valve repair at the time of left sided valve surgery for severe TR and class IIa for less than severe TR in the presence of annular dilatation (>4.0 cm) or right-sided HF [106].
Concomitant mitral valve repair can be considered in patients with ICM undergoing CABG in the presence of atrial arrhythmias, left atrial dilation, or in the setting of severe LV dilation. Replacement, rather than repair, should be considered in patients with limited viability in the posterolateral wall of the LV [97]. Tricuspid valve repair should be considered at the time of left sided valve surgery for severe TR and less than severe TR in the presence of annular dilatation (>4.0 cm), right-sided HF or iatrogenic, or lead-related injury to tricuspid leaflets. Severe TR in the presence of significant RV dysfunction is a marker of poor outcome after coronary revascularization and warrants evaluation and consideration for advanced HF therapies.
In patients with ICM, gradual dilatation of LV results in transition from elliptical to a more spherical geometry. This impairs the structure–function relationship of the left ventricle [107]. The concept of surgical ventricular restoration (SVR) procedure for the patients with ICM is more than four decades old; however, the procedure is yet to gain acceptance as not only the procedure is technically challenging but also, no study so far has been able to show consistent benefit with concomitant SVR. Doctrine of SVR operation assumes that resection of scarred myocardium, reducing the ventricular size, and restoring an anatomically elliptical shape can improve the left ventricular function [108]. However, studies so far have not been able to prove this assumption. A randomized study including 137 patients with LVEF <50% and LV end systolic volume index (LVESVI) >80 ml/m2 showed that CABG alone was inferior to CABG with SVR in terms of improvement in LVEF, MR, and NYHA class. However, study was limited to only 2 years of follow-up [109]. Similarly, Prucz et al. reported this result [110]. Both these studies were limited by short duration of follow-up and failed to show any benefit of SVR procedure on survival. Consequently, the STICH trial was conducted to evaluate the long-term outcome of concomitant SVR procedure in patients with LV dysfunction, LV akinesis/dyskinesis, presence of scar, and LV dilatation [111]. To evaluate the benefit of SVR, patients enrolled in STICH trial in CABG arm were divided into two groups (medical therapy with CABG versus medical therapy with CABG and SVR). The study found no difference in mortality between the groups at median follow-up of 48 months (hazard ratio 1.00, 95% CI 0.79–1.26, P = 0.98) [111]. Results of these studies led to abandonment of the SVR procedure by majority surgeons [112].
It still remains uncertain which patients should receive SVR as part of CABG operation and what is its impact on long-term survival and functional outcome [112, 113, 114]. Therefore, consideration for SVR should still be given to patients with true large ventricular aneurysms who present with medically refractory heart failure or ventricular arrhythmias.
Patients with ICM undergoing CABG are at increased risk of postcardiotomy shock and the risk increases further in patients with ischemic MR and/or right ventricular infarct. Patients with postcardiotomy shock who are unable to separate from cardiopulmonary bypass or require high-dose inotropic therapy, MCS should be considered [115].
Intra-aortic balloon pump has been considered as first line therapy for PCS as it is safe, widely available, and easy to place. Intra-aortic balloon pump improves the coronary perfusion, decreases the left ventricular afterload, and improves the cardiac output by 0.5–1 L/min. However, the hemodynamic support provided by an IABP is usually insufficient in reversing cardiogenic shock [116, 117]. In a recent analysis of 4550 patients operated for CABG between 2004 and 2008, 5% patients required an intraoperative or postoperative IABP, with overall mortality of 37%. IABP was equally effective in patients with predominantly right-sided failure with 50% increase in cardiac index and associated mortality of 31%. This study specifically addressed the issue of IABP effectiveness in both right- and left-sided failure [118].
Impella is a percutaneous or surgically implanted axial-flow device that is used for all types of cardiogenic shock. Impella devices significantly reduce LV end-diastolic pressure and volume, reduce myocardial oxygen demand, and support the systemic perfusion while allowing the heart to recover. EngstrÖm and colleagues [119] reported their experience with Impella 5.0 for treating 46 postcardiotomy shock patients mostly after CABG at three European centers. Half of the patients received an IABP before the Impella placement. Overall survival was 40% at 30 days. More recently, David and colleagues [120] reported on use of the Impella 5.0/Impella LD in 29 patients (40% with isolated CABG) treated for PCS between 2010 and 2015. Mortality was nearly 40%, similar to the aforementioned study. The best results for PCS treatment were reported by Griffith and colleagues [121] in the RECOVER I study, wherein an Impella 5.0 was placed in 16 patients having difficulty weaning from cardiopulmonary bypass. Fifteen patients were successfully supported, with 30-day survival of 94%. Results of this study should however be interpreted carefully as all the patients in the study were on low level of inotropic support before the Impella placement as opposed to the study protocol requirement of high inotropic support prior to Impella placement.
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is second most commonly used device after IABP for postcardiotomy shock. Veno-arterial ECMO significantly unloads the right ventricle, improves the coronary perfusion, and supports the systemic perfusion while allowing the right heart to recover. However, VA-ECMO significantly increases the left ventricular afterload. Therefore, in patients supported with VA-ECMO, it is imperative to maintain left ventricular ejection either spontaneous or with inotropes. Otherwise, left side of the heart should be vented either by atrial septostomy, left atrial/left ventricular vent, or Impella [122]. There are no RCTs regarding the effectiveness of VA-ECMO in PCS, but several retrospective studies have shown 60–70% mortality in patients with PCS despite use of VA-ECMO [122, 123, 124, 125]. In a recent report of the European registry of 781 patients receiving VA-ECMO for PCS, institution of VA-ECMO was associated with increased mortality (odds ratio 1.54; 95% CI, 1.09–2.18), reoperation for bleeding/tamponade (odds ratio, 1.96; 95% CI, 1.37–2.81), and blood transfusion of >9 units (odds ratio, 2.42; 95% CI, 1.59–3.67). The authors also did a systematic review of 2491 patients with PCS who received VA-ECMO and reported 66.6% pooled prevalence of in-hospital/30-day mortality (95% CI, 64.7–68.4%), and lower in-hospital/30-day mortality in patients with peripheral ECMO (risk ratio, 0.92; 95% CI, 0.87–0.98). Switching the patients from central to peripheral cannulation appeared to provide close to a 10% mortality benefit [126]. Finally, studies evaluating the role of LV unloading during VA-ECMO for cardiogenic shock have reported 10–20% mortality benefit with LV unloading with either Impella or IABP [127, 128].
In patients with ICM, the importance of adhering to guideline-directed medical therapy (GDMT), secondary prevention, and cardiac rehabilitation after revascularization cannot be overemphasized [129, 130]. Close follow-up of these patients is recommended for the titration of heart failure medications and continued assessment for needed additional interventions, including device implantation (e.g., automated implantable cardioverter-defibrillator (AICD)/Cardiac resynchronization therapy device (CRT) or advanced surgical therapies for persistent HF. In patients with ICM, initial 90 days after CABG are most vulnerable and associated with several-fold increase in HF-associated rehospitalization and mortality. Thus, these patients should undergo a close clinical monitoring after discharge. Initial post-discharge follow-up should be done at 7–14 days to review the volume status of the patient and titrate guideline-directed medications [131]. Although studies directly evaluating and comparing the impact of GDMT on ICM patients who have or have not undergone CABG are limited, conventional medical opinion supports that GDMT goals for post-CABG patients should not differ from those without CABG. Post hoc analysis has revealed that in patients with ICM, maintenance of optimal medical therapy after discharge is associated with best short-term and long-term outcomes [132].
Patients with ischemic cardiomyopathy and coronary artery disease that is amenable to surgical revascularization should undergo combination of surgical revascularization and medical therapy rather than medical therapy alone. This suggestion is based primarily on the long-term absolute reduction in mortality over the 10 years following CABG balanced against the early mortality risk of CABG. Routine assessment of viability to evaluate advisability of multivessel coronary revascularization to improve total mortality is not recommended. Based on the small but nontrivial early mortality risk associated with CABG surgery as well as other post-CABG morbidities, patients may also reasonably choose medical therapy as the initial treatment option. Revascularization remains an important treatment option for patients with ongoing anginal symptoms despite optimal medical therapy. For such patients, the relative efficacy of percutaneous coronary intervention (PCI) compared with CABG for revascularization is unknown. Nonrandomized registry suggests that there was no difference in mortality between CABG and PCI.
"Open access contributes to scientific excellence and integrity. It opens up research results to wider analysis. It allows research results to be reused for new discoveries. And it enables the multi-disciplinary research that is needed to solve global 21st century problems. Open access connects science with society. It allows the public to engage with research. To go behind the headlines. And look at the scientific evidence. And it enables policy makers to draw on innovative solutions to societal challenges".
\n\nCarlos Moedas, the European Commissioner for Research Science and Innovation at the STM Annual Frankfurt Conference, October 2016.
",metaTitle:"About Open Access",metaDescription:"Open access contributes to scientific excellence and integrity. It opens up research results to wider analysis. It allows research results to be reused for new discoveries. And it enables the multi-disciplinary research that is needed to solve global 21st century problems. Open access connects science with society. It allows the public to engage with research. To go behind the headlines. And look at the scientific evidence. And it enables policy makers to draw on innovative solutions to societal challenges.\n\nCarlos Moedas, the European Commissioner for Research Science and Innovation at the STM Annual Frankfurt Conference, October 2016.",metaKeywords:null,canonicalURL:"about-open-access",contentRaw:'[{"type":"htmlEditorComponent","content":"The Open Access publishing movement started in the early 2000s when academic leaders from around the world participated in the formation of the Budapest Initiative. They developed recommendations for an Open Access publishing process, “which has worked for the past decade to provide the public with unrestricted, free access to scholarly research—much of which is publicly funded. Making the research publicly available to everyone—free of charge and without most copyright and licensing restrictions—will accelerate scientific research efforts and allow authors to reach a larger number of readers” (reference: http://www.budapestopenaccessinitiative.org)
\\n\\nIntechOpen’s co-founders, both scientists themselves, created the company while undertaking research in robotics at Vienna University. Their goal was to spread research freely “for scientists, by scientists’ to the rest of the world via the Open Access publishing model. The company soon became a signatory of the Budapest Initiative, which currently has more than 1000 supporting organizations worldwide, ranging from universities to funders.
\\n\\nAt IntechOpen today, we are still as committed to working with organizations and people who care about scientific discovery, to putting the academic needs of the scientific community first, and to providing an Open Access environment where scientists can maximize their contribution to scientific advancement. By opening up access to the world’s scientific research articles and book chapters, we aim to facilitate greater opportunity for collaboration, scientific discovery and progress. We subscribe wholeheartedly to the Open Access definition:
\\n\\n“By “open access” to [peer-reviewed research literature], we mean its free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited” (reference: http://www.budapestopenaccessinitiative.org)
\\n\\nOAI-PMH
\\n\\nAs a firm believer in the wider dissemination of knowledge, IntechOpen supports the Open Access Initiative Protocol for Metadata Harvesting (OAI-PMH Version 2.0). Read more
\\n\\nLicense
\\n\\nBook chapters published in edited volumes are distributed under the Creative Commons Attribution 3.0 Unported License (CC BY 3.0). IntechOpen upholds a very flexible Copyright Policy. There is no copyright transfer to the publisher and Authors retain exclusive copyright to their work. All Monographs/Compacts are distributed under the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Read more
\\n\\nPeer Review Policies
\\n\\nAll scientific works are Peer Reviewed prior to publishing. Read more
\\n\\nOA Publishing Fees
\\n\\nThe Open Access publishing model employed by IntechOpen eliminates subscription charges and pay-per-view fees, enabling readers to access research at no cost. In order to sustain operations and keep our publications freely accessible we levy an Open Access Publishing Fee for manuscripts, which helps us cover the costs of editorial work and the production of books. Read more
\\n\\nDigital Archiving Policy
\\n\\nIntechOpen is committed to ensuring the long-term preservation and the availability of all scholarly research we publish. We employ a variety of means to enable us to deliver on our commitments to the scientific community. Apart from preservation by the Croatian National Library (for publications prior to April 18, 2018) and the British Library (for publications after April 18, 2018), our entire catalogue is preserved in the CLOCKSS archive.
\\n\\nOpen Science is transparent and accessible knowledge that is shared and developed through collaborative networks.
\\n\\nOpen Science is about increased rigour, accountability, and reproducibility for research. It is based on the principles of inclusion, fairness, equity, and sharing, and ultimately seeks to change the way research is done, who is involved and how it is valued. It aims to make research more open to participation, review/refutation, improvement and (re)use for the world to benefit.
\\n\\nOpen Science refers to doing traditional science with more transparency involved at various stages, for example by openly sharing code and data. It implies a growing set of practices - within different disciplines - aiming at:
\\n\\nWe aim at improving the quality and availability of scholarly communication by promoting and practicing:
\\n\\n\\n"}]'},components:[{type:"htmlEditorComponent",content:'
The Open Access publishing movement started in the early 2000s when academic leaders from around the world participated in the formation of the Budapest Initiative. They developed recommendations for an Open Access publishing process, “which has worked for the past decade to provide the public with unrestricted, free access to scholarly research—much of which is publicly funded. Making the research publicly available to everyone—free of charge and without most copyright and licensing restrictions—will accelerate scientific research efforts and allow authors to reach a larger number of readers” (reference: http://www.budapestopenaccessinitiative.org)
\n\nIntechOpen’s co-founders, both scientists themselves, created the company while undertaking research in robotics at Vienna University. Their goal was to spread research freely “for scientists, by scientists’ to the rest of the world via the Open Access publishing model. The company soon became a signatory of the Budapest Initiative, which currently has more than 1000 supporting organizations worldwide, ranging from universities to funders.
\n\nAt IntechOpen today, we are still as committed to working with organizations and people who care about scientific discovery, to putting the academic needs of the scientific community first, and to providing an Open Access environment where scientists can maximize their contribution to scientific advancement. By opening up access to the world’s scientific research articles and book chapters, we aim to facilitate greater opportunity for collaboration, scientific discovery and progress. We subscribe wholeheartedly to the Open Access definition:
\n\n“By “open access” to [peer-reviewed research literature], we mean its free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited” (reference: http://www.budapestopenaccessinitiative.org)
\n\nOAI-PMH
\n\nAs a firm believer in the wider dissemination of knowledge, IntechOpen supports the Open Access Initiative Protocol for Metadata Harvesting (OAI-PMH Version 2.0). Read more
\n\nLicense
\n\nBook chapters published in edited volumes are distributed under the Creative Commons Attribution 3.0 Unported License (CC BY 3.0). IntechOpen upholds a very flexible Copyright Policy. There is no copyright transfer to the publisher and Authors retain exclusive copyright to their work. All Monographs/Compacts are distributed under the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Read more
\n\nPeer Review Policies
\n\nAll scientific works are Peer Reviewed prior to publishing. Read more
\n\nOA Publishing Fees
\n\nThe Open Access publishing model employed by IntechOpen eliminates subscription charges and pay-per-view fees, enabling readers to access research at no cost. In order to sustain operations and keep our publications freely accessible we levy an Open Access Publishing Fee for manuscripts, which helps us cover the costs of editorial work and the production of books. Read more
\n\nDigital Archiving Policy
\n\nIntechOpen is committed to ensuring the long-term preservation and the availability of all scholarly research we publish. We employ a variety of means to enable us to deliver on our commitments to the scientific community. Apart from preservation by the Croatian National Library (for publications prior to April 18, 2018) and the British Library (for publications after April 18, 2018), our entire catalogue is preserved in the CLOCKSS archive.
\n\nOpen Science is transparent and accessible knowledge that is shared and developed through collaborative networks.
\n\nOpen Science is about increased rigour, accountability, and reproducibility for research. It is based on the principles of inclusion, fairness, equity, and sharing, and ultimately seeks to change the way research is done, who is involved and how it is valued. It aims to make research more open to participation, review/refutation, improvement and (re)use for the world to benefit.
\n\nOpen Science refers to doing traditional science with more transparency involved at various stages, for example by openly sharing code and data. It implies a growing set of practices - within different disciplines - aiming at:
\n\nWe aim at improving the quality and availability of scholarly communication by promoting and practicing:
\n\n\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{},profiles:[{id:"396",title:"Dr.",name:"Vedran",middleName:null,surname:"Kordic",slug:"vedran-kordic",fullName:"Vedran Kordic",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/396/images/7281_n.png",biography:"After obtaining his Master's degree in Mechanical Engineering he continued his education at the Vienna University of Technology where he obtained his PhD degree in 2004. He worked as a researcher at the Automation and Control Institute, Faculty of Electrical Engineering, Vienna University of Technology until 2008. His studies in robotics lead him not only to a PhD degree but also inspired him to co-found and build the International Journal of Advanced Robotic Systems - world's first Open Access journal in the field of robotics.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"441",title:"Ph.D.",name:"Jaekyu",middleName:null,surname:"Park",slug:"jaekyu-park",fullName:"Jaekyu Park",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/441/images/1881_n.jpg",biography:null,institutionString:null,institution:{name:"LG Corporation (South Korea)",country:{name:"Korea, South"}}},{id:"465",title:"Dr",name:"Christian",middleName:null,surname:"Martens",slug:"christian-martens",fullName:"Christian Martens",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"479",title:"Dr.",name:"Valentina",middleName:null,surname:"Colla",slug:"valentina-colla",fullName:"Valentina Colla",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/479/images/358_n.jpg",biography:null,institutionString:null,institution:{name:"Sant'Anna School of Advanced Studies",country:{name:"Italy"}}},{id:"494",title:"PhD",name:"Loris",middleName:null,surname:"Nanni",slug:"loris-nanni",fullName:"Loris Nanni",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/494/images/system/494.jpg",biography:"Loris Nanni received his Master Degree cum laude on June-2002 from the University of Bologna, and the April 26th 2006 he received his Ph.D. in Computer Engineering at DEIS, University of Bologna. On September, 29th 2006 he has won a post PhD fellowship from the university of Bologna (from October 2006 to October 2008), at the competitive examination he was ranked first in the industrial engineering area. He extensively served as referee for several international journals. He is author/coauthor of more than 100 research papers. He has been involved in some projects supported by MURST and European Community. His research interests include pattern recognition, bioinformatics, and biometric systems (fingerprint classification and recognition, signature verification, face recognition).",institutionString:null,institution:null},{id:"496",title:"Dr.",name:"Carlos",middleName:null,surname:"Leon",slug:"carlos-leon",fullName:"Carlos Leon",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Seville",country:{name:"Spain"}}},{id:"512",title:"Dr.",name:"Dayang",middleName:null,surname:"Jawawi",slug:"dayang-jawawi",fullName:"Dayang Jawawi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Technology Malaysia",country:{name:"Malaysia"}}},{id:"528",title:"Dr.",name:"Kresimir",middleName:null,surname:"Delac",slug:"kresimir-delac",fullName:"Kresimir Delac",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/528/images/system/528.jpg",biography:"K. Delac received his B.Sc.E.E. degree in 2003 and is currentlypursuing a Ph.D. degree at the University of Zagreb, Faculty of Electrical Engineering andComputing. His current research interests are digital image analysis, pattern recognition andbiometrics.",institutionString:null,institution:{name:"University of Zagreb",country:{name:"Croatia"}}},{id:"557",title:"Dr.",name:"Andon",middleName:"Venelinov",surname:"Topalov",slug:"andon-topalov",fullName:"Andon Topalov",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/557/images/1927_n.jpg",biography:"Dr. Andon V. Topalov received the MSc degree in Control Engineering from the Faculty of Information Systems, Technologies, and Automation at Moscow State University of Civil Engineering (MGGU) in 1979. He then received his PhD degree in Control Engineering from the Department of Automation and Remote Control at Moscow State Mining University (MGSU), Moscow, in 1984. From 1985 to 1986, he was a Research Fellow in the Research Institute for Electronic Equipment, ZZU AD, Plovdiv, Bulgaria. In 1986, he joined the Department of Control Systems, Technical University of Sofia at the Plovdiv campus, where he is presently a Full Professor. He has held long-term visiting Professor/Scholar positions at various institutions in South Korea, Turkey, Mexico, Greece, Belgium, UK, and Germany. And he has coauthored one book and authored or coauthored more than 80 research papers in conference proceedings and journals. His current research interests are in the fields of intelligent control and robotics.",institutionString:null,institution:{name:"Technical University of Sofia",country:{name:"Bulgaria"}}},{id:"585",title:"Prof.",name:"Munir",middleName:null,surname:"Merdan",slug:"munir-merdan",fullName:"Munir Merdan",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/585/images/system/585.jpg",biography:"Munir Merdan received the M.Sc. degree in mechanical engineering from the Technical University of Sarajevo, Bosnia and Herzegovina, in 2001, and the Ph.D. degree in electrical engineering from the Vienna University of Technology, Vienna, Austria, in 2009.Since 2005, he has been at the Automation and Control Institute, Vienna University of Technology, where he is currently a Senior Researcher. His research interests include the application of agent technology for achieving agile control in the manufacturing environment.",institutionString:null,institution:null},{id:"605",title:"Prof",name:"Dil",middleName:null,surname:"Hussain",slug:"dil-hussain",fullName:"Dil Hussain",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/605/images/system/605.jpg",biography:"Dr. Dil Muhammad Akbar Hussain is a professor of Electronics Engineering & Computer Science at the Department of Energy Technology, Aalborg University Denmark. Professor Akbar has a Master degree in Digital Electronics from Govt. College University, Lahore Pakistan and a P-hD degree in Control Engineering from the School of Engineering and Applied Sciences, University of Sussex United Kingdom. Aalborg University has Two Satellite Campuses, one in Copenhagen (Aalborg University Copenhagen) and the other in Esbjerg (Aalborg University Esbjerg).\n· He is a member of prestigious IEEE (Institute of Electrical and Electronics Engineers), and IAENG (International Association of Engineers) organizations. \n· He is the chief Editor of the Journal of Software Engineering.\n· He is the member of the Editorial Board of International Journal of Computer Science and Software Technology (IJCSST) and International Journal of Computer Engineering and Information Technology. \n· He is also the Editor of Communication in Computer and Information Science CCIS-20 by Springer.\n· Reviewer For Many Conferences\nHe is the lead person in making collaboration agreements between Aalborg University and many universities of Pakistan, for which the MOU’s (Memorandum of Understanding) have been signed.\nProfessor Akbar is working in Academia since 1990, he started his career as a Lab demonstrator/TA at the University of Sussex. After finishing his P. hD degree in 1992, he served in the Industry as a Scientific Officer and continued his academic career as a visiting scholar for a number of educational institutions. In 1996 he joined National University of Science & Technology Pakistan (NUST) as an Associate Professor; NUST is one of the top few universities in Pakistan. In 1999 he joined an International Company Lineo Inc, Canada as Manager Compiler Group, where he headed the group for developing Compiler Tool Chain and Porting of Operating Systems for the BLACKfin processor. The processor development was a joint venture by Intel and Analog Devices. In 2002 Lineo Inc., was taken over by another company, so he joined Aalborg University Denmark as an Assistant Professor.\nProfessor Akbar has truly a multi-disciplined career and he continued his legacy and making progress in many areas of his interests both in teaching and research. He has contributed in stochastic estimation of control area especially, in the Multiple Target Tracking and Interactive Multiple Model (IMM) research, Ball & Beam Control Problem, Robotics, Levitation Control. He has contributed in developing Algorithms for Fingerprint Matching, Computer Vision and Face Recognition. He has been supervising Pattern Recognition, Formal Languages and Distributed Processing projects for several years. He has reviewed many books on Management, Computer Science. Currently, he is an active and permanent reviewer for many international conferences and symposia and the program committee member for many international conferences.\nIn teaching he has taught the core computer science subjects like, Digital Design, Real Time Embedded System Programming, Operating Systems, Software Engineering, Data Structures, Databases, Compiler Construction. In the Engineering side, Digital Signal Processing, Computer Architecture, Electronics Devices, Digital Filtering and Engineering Management.\nApart from his Academic Interest and activities he loves sport especially, Cricket, Football, Snooker and Squash. He plays cricket for Esbjerg city in the second division team as an opener wicket keeper batsman. He is a very good player of squash but has not played squash since his arrival in Denmark.",institutionString:null,institution:null},{id:"611",title:"Prof.",name:"T",middleName:null,surname:"Nagarajan",slug:"t-nagarajan",fullName:"T Nagarajan",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universiti Teknologi Petronas",country:{name:"Malaysia"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:6602},{group:"region",caption:"Middle and South America",value:2,count:5908},{group:"region",caption:"Africa",value:3,count:2400},{group:"region",caption:"Asia",value:4,count:12542},{group:"region",caption:"Australia and Oceania",value:5,count:1008},{group:"region",caption:"Europe",value:6,count:17561}],offset:12,limit:12,total:132766},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{hasNoEditors:"0",sort:"dateEndThirdStepPublish"},books:[{type:"book",id:"11648",title:"Current Status and Ecological Aspects of Seabirds",subtitle:null,isOpenForSubmission:!0,hash:"7754b354f7deebdb8576189aefbdbc5c",slug:null,bookSignature:"Dr. Muhammad Nawaz Rajpar",coverURL:"https://cdn.intechopen.com/books/images_new/11648.jpg",editedByType:null,editors:[{id:"183095",title:"Dr.",name:"Muhammad Nawaz",surname:"Rajpar",slug:"muhammad-nawaz-rajpar",fullName:"Muhammad Nawaz Rajpar"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11561",title:"Zeolite From Wastes - New Perspectives on Innovative Resources and Their Valorization Process",subtitle:null,isOpenForSubmission:!0,hash:"3ed0dfd842de9cd1143212415903e6ad",slug:null,bookSignature:"Dr. Claudia Belviso",coverURL:"https://cdn.intechopen.com/books/images_new/11561.jpg",editedByType:null,editors:[{id:"61457",title:"Dr.",name:"Claudia",surname:"Belviso",slug:"claudia-belviso",fullName:"Claudia Belviso"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11470",title:"Graphene - Recent Advances, Future Perspective and Applied Applications",subtitle:null,isOpenForSubmission:!0,hash:"409e022e3baf48795e816576a6ee66e3",slug:null,bookSignature:"Dr. Mujtaba Ikram, Dr. Asghari Maqsood and Dr. Aneeqa Bashir",coverURL:"https://cdn.intechopen.com/books/images_new/11470.jpg",editedByType:null,editors:[{id:"286820",title:"Dr.",name:"Mujtaba",surname:"Ikram",slug:"mujtaba-ikram",fullName:"Mujtaba Ikram"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11600",title:"Recent Update on Multiple Myeloma\ufeff",subtitle:null,isOpenForSubmission:!0,hash:"c8e2b12df4fc2d313aced448fe08a63e",slug:null,bookSignature:"Dr. Khalid Ahmed Al-Anazi",coverURL:"https://cdn.intechopen.com/books/images_new/11600.jpg",editedByType:null,editors:[{id:"37255",title:"Dr.",name:"Khalid",surname:"Al-Anazi",slug:"khalid-al-anazi",fullName:"Khalid Al-Anazi"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11586",title:"Schizophrenia - Recent Advances and Patient-Centered Treatment Perspectives",subtitle:null,isOpenForSubmission:!0,hash:"2ba14221aca01660b2547004d9b5c2d9",slug:null,bookSignature:"Dr. Jane Yip",coverURL:"https://cdn.intechopen.com/books/images_new/11586.jpg",editedByType:null,editors:[{id:"156214",title:"Dr.",name:"Jane",surname:"Yip",slug:"jane-yip",fullName:"Jane Yip"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11519",title:"Vibration Monitoring and Analysis - Recent Advances",subtitle:null,isOpenForSubmission:!0,hash:"f0d2d82a5c1a49020abf39dc8aabd89d",slug:null,bookSignature:"Dr.Ing. Louay Yousuf",coverURL:"https://cdn.intechopen.com/books/images_new/11519.jpg",editedByType:null,editors:[{id:"322417",title:"Dr.Ing.",name:"Louay",surname:"Yousuf",slug:"louay-yousuf",fullName:"Louay Yousuf"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11445",title:"Multi-Agent Technologies and Machine Learning",subtitle:null,isOpenForSubmission:!0,hash:"d980826615baa6e33456e2a79064c5e8",slug:null,bookSignature:"Prof. Igor Sheremet",coverURL:"https://cdn.intechopen.com/books/images_new/11445.jpg",editedByType:null,editors:[{id:"265237",title:"Prof.",name:"Igor",surname:"Sheremet",slug:"igor-sheremet",fullName:"Igor Sheremet"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11468",title:"High Entropy Alloys - Recent Advances, New Perspectives and Applications",subtitle:null,isOpenForSubmission:!0,hash:"3b4ef3ce01f8f9b113dc28ac847b8c0d",slug:null,bookSignature:"Prof. Yong A Zhang",coverURL:"https://cdn.intechopen.com/books/images_new/11468.jpg",editedByType:null,editors:[{id:"203937",title:"Prof.",name:"Yong",surname:"Zhang",slug:"yong-zhang",fullName:"Yong Zhang"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11525",title:"Wood Industry - Past, Present and Future Outlook",subtitle:null,isOpenForSubmission:!0,hash:"ccb74142053c89e0e572ac1c5d717a11",slug:null,bookSignature:"Prof. Guanben Du and Dr. Xiaojian Zhou",coverURL:"https://cdn.intechopen.com/books/images_new/11525.jpg",editedByType:null,editors:[{id:"291315",title:"Prof.",name:"Guanben",surname:"Du",slug:"guanben-du",fullName:"Guanben Du"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11484",title:"Thin Film Deposition - Fundamentals, Processes, and Applications",subtitle:null,isOpenForSubmission:!0,hash:"9c10a55203c2f0f7d47c743e6cfa2492",slug:null,bookSignature:"Dr. Dongfang Yang",coverURL:"https://cdn.intechopen.com/books/images_new/11484.jpg",editedByType:null,editors:[{id:"177814",title:"Dr.",name:"Dongfang",surname:"Yang",slug:"dongfang-yang",fullName:"Dongfang Yang"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11620",title:"Tomato - From Cultivation to Processing Technology",subtitle:null,isOpenForSubmission:!0,hash:"cdc23b5aad5d52bc0f0327c453ac7a1b",slug:null,bookSignature:"Prof. Pranas Viskelis, Dr. Dalia Urbonavičienė and Dr. Jonas Viskelis",coverURL:"https://cdn.intechopen.com/books/images_new/11620.jpg",editedByType:null,editors:[{id:"83785",title:"Prof.",name:"Pranas",surname:"Viskelis",slug:"pranas-viskelis",fullName:"Pranas Viskelis"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11597",title:"Glioblastoma - Current Evidences",subtitle:null,isOpenForSubmission:!0,hash:"da69711754eb5ed95bdea15fcfab0b2a",slug:null,bookSignature:"Prof. Amit Agrawal",coverURL:"https://cdn.intechopen.com/books/images_new/11597.jpg",editedByType:null,editors:[{id:"100142",title:"Prof.",name:"Amit",surname:"Agrawal",slug:"amit-agrawal",fullName:"Amit Agrawal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:43},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:12},{group:"topic",caption:"Business, Management and Economics",value:7,count:4},{group:"topic",caption:"Chemistry",value:8,count:24},{group:"topic",caption:"Computer and Information Science",value:9,count:19},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:17},{group:"topic",caption:"Engineering",value:11,count:61},{group:"topic",caption:"Environmental Sciences",value:12,count:9},{group:"topic",caption:"Immunology and Microbiology",value:13,count:10},{group:"topic",caption:"Materials Science",value:14,count:29},{group:"topic",caption:"Mathematics",value:15,count:11},{group:"topic",caption:"Medicine",value:16,count:124},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:9},{group:"topic",caption:"Neuroscience",value:18,count:3},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:6},{group:"topic",caption:"Physics",value:20,count:12},{group:"topic",caption:"Psychology",value:21,count:9},{group:"topic",caption:"Robotics",value:22,count:3},{group:"topic",caption:"Social Sciences",value:23,count:9},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:3}],offset:12,limit:12,total:419},popularBooks:{featuredBooks:[],offset:0,limit:12,total:null},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[],latestBooks:[]},subject:{topic:{id:"24",title:"Technology",slug:"technology",parent:{id:"1",title:"Physical Sciences, Engineering and Technology",slug:"physical-sciences-engineering-and-technology"},numberOfBooks:128,numberOfSeries:0,numberOfAuthorsAndEditors:2388,numberOfWosCitations:3395,numberOfCrossrefCitations:2339,numberOfDimensionsCitations:5170,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicId:"24",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"10968",title:"Applied Aspects of Modern Metrology",subtitle:null,isOpenForSubmission:!1,hash:"688f4a581f96ea8041bc2dff50f6256e",slug:"applied-aspects-of-modern-metrology",bookSignature:"Oleh Velychko",coverURL:"https://cdn.intechopen.com/books/images_new/10968.jpg",editedByType:"Edited by",editors:[{id:"223340",title:"Prof.",name:"Oleh",middleName:null,surname:"Velychko",slug:"oleh-velychko",fullName:"Oleh Velychko"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10805",title:"Technology, Science and Culture",subtitle:"A Global Vision, Volume III",isOpenForSubmission:!1,hash:"d023002df29a59c64622b5b5936e2b67",slug:"technology-science-and-culture-a-global-vision-volume-iii",bookSignature:"Luis Ricardo Hernández and Martín Alejandro Serrano Meneses",coverURL:"https://cdn.intechopen.com/books/images_new/10805.jpg",editedByType:"Edited by",editors:[{id:"293965",title:"Dr.",name:"Luis Ricardo",middleName:null,surname:"Hernández",slug:"luis-ricardo-hernandez",fullName:"Luis Ricardo Hernández"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"2",chapterContentType:"conference paper",authoredCaption:"Edited by"}},{type:"book",id:"10668",title:"Sustainability of Concrete With Synthetic and Recycled Aggregates",subtitle:null,isOpenForSubmission:!1,hash:"55856c6a8bc3a5b21dae5a1af09a56b6",slug:"sustainability-of-concrete-with-synthetic-and-recycled-aggregates",bookSignature:"Hosam M. Saleh",coverURL:"https://cdn.intechopen.com/books/images_new/10668.jpg",editedByType:"Edited by",editors:[{id:"144691",title:"Prof.",name:"Hosam",middleName:null,surname:"Saleh",slug:"hosam-saleh",fullName:"Hosam Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10584",title:"Engineered Wood Products for Construction",subtitle:null,isOpenForSubmission:!1,hash:"421757c56a3735986055250821275a51",slug:"engineered-wood-products-for-construction",bookSignature:"Meng Gong",coverURL:"https://cdn.intechopen.com/books/images_new/10584.jpg",editedByType:"Edited by",editors:[{id:"274242",title:"Dr.",name:"Meng",middleName:null,surname:"Gong",slug:"meng-gong",fullName:"Meng Gong"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10975",title:"Sewage",subtitle:"Recent Advances, New Perspectives and Applications",isOpenForSubmission:!1,hash:"0933f9b6aa7b8c65e710e951e674997d",slug:"sewage-recent-advances-new-perspectives-and-applications",bookSignature:"Tao Zhang",coverURL:"https://cdn.intechopen.com/books/images_new/10975.jpg",editedByType:"Edited by",editors:[{id:"185487",title:"Associate Prof.",name:"Tao",middleName:null,surname:"Zhang",slug:"tao-zhang",fullName:"Tao Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10389",title:"Osmotically Driven Membrane Processes",subtitle:null,isOpenForSubmission:!1,hash:"d5bb1865e5a17251d299b5c1ada3f5c0",slug:"osmotically-driven-membrane-processes",bookSignature:"Muharrem Ince and Olcay Kaplan Ince",coverURL:"https://cdn.intechopen.com/books/images_new/10389.jpg",editedByType:"Edited by",editors:[{id:"258431",title:"Prof.",name:"Muharrem",middleName:null,surname:"Ince",slug:"muharrem-ince",fullName:"Muharrem Ince"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10410",title:"Textiles for Functional Applications",subtitle:null,isOpenForSubmission:!1,hash:"5be34ee24510dc6ac217b82f0ce41ab0",slug:"textiles-for-functional-applications",bookSignature:"Bipin Kumar",coverURL:"https://cdn.intechopen.com/books/images_new/10410.jpg",editedByType:"Edited by",editors:[{id:"177114",title:"Dr.",name:"Bipin",middleName:null,surname:"Kumar",slug:"bipin-kumar",fullName:"Bipin Kumar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9921",title:"Promising Techniques for Wastewater Treatment and Water Quality Assessment",subtitle:null,isOpenForSubmission:!1,hash:"59ea12a5ea4a235dc8123537effc7cf1",slug:"promising-techniques-for-wastewater-treatment-and-water-quality-assessment",bookSignature:"Iqbal Ahmed Moujdin and J. Kevin Summers",coverURL:"https://cdn.intechopen.com/books/images_new/9921.jpg",editedByType:"Edited by",editors:[{id:"197244",title:"Associate Prof.",name:"Iqbal",middleName:null,surname:"Ahmed",slug:"iqbal-ahmed",fullName:"Iqbal Ahmed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10548",title:"Lean Manufacturing",subtitle:null,isOpenForSubmission:!1,hash:"7409b2acd5150a93004300800918b736",slug:"lean-manufacturing",bookSignature:"Karmen Pažek",coverURL:"https://cdn.intechopen.com/books/images_new/10548.jpg",editedByType:"Edited by",editors:[{id:"179642",title:"Prof.",name:"Karmen",middleName:null,surname:"Pažek",slug:"karmen-pazek",fullName:"Karmen Pažek"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6940",title:"e-Services",subtitle:null,isOpenForSubmission:!1,hash:"0dd6e0f6c0a6d3be53af40ae99a1529d",slug:"e-services",bookSignature:"Sam Goundar",coverURL:"https://cdn.intechopen.com/books/images_new/6940.jpg",editedByType:"Edited by",editors:[{id:"280395",title:"Dr.",name:"Sam",middleName:null,surname:"Goundar",slug:"sam-goundar",fullName:"Sam Goundar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10203",title:"Dyes and Pigments",subtitle:"Novel Applications and Waste Treatment",isOpenForSubmission:!1,hash:"624f533946a159bc8a03f109c2e1dc91",slug:"dyes-and-pigments-novel-applications-and-waste-treatment",bookSignature:"Raffaello Papadakis",coverURL:"https://cdn.intechopen.com/books/images_new/10203.jpg",editedByType:"Edited by",editors:[{id:"251885",title:"Dr.",name:"Raffaello",middleName:null,surname:"Papadakis",slug:"raffaello-papadakis",fullName:"Raffaello Papadakis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10060",title:"Cement Industry",subtitle:"Optimization, Characterization and Sustainable Application",isOpenForSubmission:!1,hash:"9a1e79b25dad63378b81fdb16909cd09",slug:"cement-industry-optimization-characterization-and-sustainable-application",bookSignature:"Hosam El-Din Mostafa Saleh",coverURL:"https://cdn.intechopen.com/books/images_new/10060.jpg",editedByType:"Edited by",editors:[{id:"144691",title:"Prof.",name:"Hosam",middleName:null,surname:"Saleh",slug:"hosam-saleh",fullName:"Hosam Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:128,seriesByTopicCollection:[],seriesByTopicTotal:0,mostCitedChapters:[{id:"41411",doi:"10.5772/53659",title:"Textile Dyes: Dyeing Process and Environmental Impact",slug:"textile-dyes-dyeing-process-and-environmental-impact",totalDownloads:20534,totalCrossrefCites:92,totalDimensionsCites:299,abstract:null,book:{id:"3137",slug:"eco-friendly-textile-dyeing-and-finishing",title:"Eco-Friendly Textile Dyeing and Finishing",fullTitle:"Eco-Friendly Textile Dyeing and Finishing"},signatures:"Farah Maria Drumond Chequer, Gisele Augusto Rodrigues de Oliveira, Elisa Raquel Anastácio Ferraz, Juliano Carvalho Cardoso, Maria Valnice Boldrin Zanoni and Danielle Palma de Oliveira",authors:[{id:"49040",title:"Prof.",name:"Danielle",middleName:null,surname:"Palma De Oliveira",slug:"danielle-palma-de-oliveira",fullName:"Danielle Palma De Oliveira"},{id:"149074",title:"Prof.",name:"Maria Valnice",middleName:null,surname:"Zanoni",slug:"maria-valnice-zanoni",fullName:"Maria Valnice Zanoni"},{id:"153502",title:"Ph.D.",name:"Farah",middleName:null,surname:"Chequer",slug:"farah-chequer",fullName:"Farah Chequer"},{id:"153504",title:"MSc.",name:"Gisele",middleName:null,surname:"Oliveira",slug:"gisele-oliveira",fullName:"Gisele Oliveira"},{id:"163377",title:"Dr.",name:"Juliano",middleName:null,surname:"Cardoso",slug:"juliano-cardoso",fullName:"Juliano Cardoso"},{id:"163393",title:"Dr.",name:"Elisa",middleName:null,surname:"Ferraz",slug:"elisa-ferraz",fullName:"Elisa Ferraz"}]},{id:"22395",doi:"10.5772/22670",title:"Textile Dyeing Wastewater Treatment",slug:"textile-dyeing-wastewater-treatment",totalDownloads:61265,totalCrossrefCites:59,totalDimensionsCites:141,abstract:null,book:{id:"528",slug:"advances-in-treating-textile-effluent",title:"Advances in Treating Textile Effluent",fullTitle:"Advances in Treating Textile Effluent"},signatures:"Zongping Wang, Miaomiao Xue, Kai Huang and Zizheng Liu",authors:[{id:"48655",title:"Dr.",name:"Zongping",middleName:null,surname:"Wang",slug:"zongping-wang",fullName:"Zongping Wang"},{id:"137783",title:"Prof.",name:"Miaomiao",middleName:null,surname:"Xue",slug:"miaomiao-xue",fullName:"Miaomiao Xue"},{id:"137784",title:"Prof.",name:"Kai",middleName:null,surname:"Huang",slug:"kai-huang",fullName:"Kai Huang"},{id:"137785",title:"Prof.",name:"Zizheng",middleName:null,surname:"Liu",slug:"zizheng-liu",fullName:"Zizheng Liu"}]},{id:"23051",doi:"10.5772/21341",title:"Dyeing of Textiles with Natural Dyes",slug:"dyeing-of-textiles-with-natural-dyes",totalDownloads:48102,totalCrossrefCites:16,totalDimensionsCites:91,abstract:null,book:{id:"1351",slug:"natural-dyes",title:"Natural Dyes",fullTitle:"Natural Dyes"},signatures:"Ashis Kumar Samanta and Adwaita Konar",authors:[{id:"42763",title:"Prof.",name:"Ashis Kumar",middleName:null,surname:"Samanta",slug:"ashis-kumar-samanta",fullName:"Ashis Kumar Samanta"},{id:"50085",title:"Mr.",name:"Adwaita",middleName:null,surname:"Konar",slug:"adwaita-konar",fullName:"Adwaita Konar"}]},{id:"31905",doi:"10.5772/38302",title:"Touch Screens for the Older User",slug:"touch-screens-for-the-older-user",totalDownloads:5105,totalCrossrefCites:51,totalDimensionsCites:80,abstract:null,book:{id:"577",slug:"assistive-technologies",title:"Assistive Technologies",fullTitle:"Assistive Technologies"},signatures:"Niamh Caprani, Noel E. O’Connor and Cathal Gurrin",authors:[{id:"1479",title:"Dr.",name:"Cathal",middleName:null,surname:"Gurrin",slug:"cathal-gurrin",fullName:"Cathal Gurrin"},{id:"116543",title:"Ms.",name:"Niamh",middleName:null,surname:"Caprani",slug:"niamh-caprani",fullName:"Niamh Caprani"},{id:"116548",title:"Prof.",name:"Noel",middleName:null,surname:"E. O'Connor",slug:"noel-e.-o'connor",fullName:"Noel E. O'Connor"}]},{id:"12253",doi:"10.5772/10465",title:"Composites Based on Natural Fibre Fabrics",slug:"composites-based-on-natural-fibre-fabrics",totalDownloads:27471,totalCrossrefCites:24,totalDimensionsCites:75,abstract:null,book:{id:"3682",slug:"woven-fabric-engineering",title:"Woven Fabric Engineering",fullTitle:"Woven Fabric Engineering"},signatures:"Gianluca Cicala, Giuseppe Cristaldi, Giuseppe Recca and Alberta Latteri",authors:null}],mostDownloadedChaptersLast30Days:[{id:"70605",title:"Designing a Tunnel",slug:"designing-a-tunnel",totalDownloads:2701,totalCrossrefCites:2,totalDimensionsCites:3,abstract:"Designing a tunnel is always a challenge. For shallow tunnels under cities due to the presence of buildings, bridges, important avenues, antiquities, etc. at the surface and other infrastructures in the vicinity of underground tunnels, parameters like vibrations and ground settlements must be tightly controlled. Urban tunnels are often made in soils with very low values of overburden. Risks of collapse and large deformations at the surface are high; thus negative impact on old buildings are likely to occur if appropriate measures are not taken in advance, when designing and constructing the tunnel. For deep tunnels with high overburden and low rock mass properties, squeezing conditions and excessive loads around the excavation can jeopardize the stability of the tunnel, leading to extensive collapse. The aim of the chapter is to give details on advance computational modelling and analytical methodologies, which can be used in order to design shallow and deep tunnels and to present real case studies from around the world, from very shallow tunnels in India with only 4.5 m overburden to a deep tunnel in Venezuela with extreme squeezing conditions under 1300 m overburden.",book:{id:"7690",slug:"tunnel-engineering-selected-topics",title:"Tunnel Engineering",fullTitle:"Tunnel Engineering - Selected Topics"},signatures:"Spiros Massinas",authors:[{id:"295762",title:"Dr.",name:"Spiros",middleName:null,surname:"Massinas",slug:"spiros-massinas",fullName:"Spiros Massinas"}]},{id:"68157",title:"Introductory Chapter: Textile Manufacturing Processes",slug:"introductory-chapter-textile-manufacturing-processes",totalDownloads:4361,totalCrossrefCites:13,totalDimensionsCites:23,abstract:null,book:{id:"8892",slug:"textile-manufacturing-processes",title:"Textile Manufacturing Processes",fullTitle:"Textile Manufacturing Processes"},signatures:"Faheem Uddin",authors:[{id:"228107",title:"Prof.",name:"Faheem",middleName:null,surname:"Uddin",slug:"faheem-uddin",fullName:"Faheem Uddin"}]},{id:"66828",title:"Breathing Monitoring and Pattern Recognition with Wearable Sensors",slug:"breathing-monitoring-and-pattern-recognition-with-wearable-sensors",totalDownloads:3024,totalCrossrefCites:10,totalDimensionsCites:13,abstract:"This chapter introduces the anatomy and physiology of the respiratory system, and the reasons for measuring breathing events, particularly, using wearable sensors. Respiratory monitoring is vital including detection of sleep apnea and measurement of respiratory rate. The automatic detection of breathing patterns is equally important in other respiratory rehabilitation therapies, for example, magnetic resonance exams for respiratory triggered imaging, and synchronized functional electrical stimulation. In this context, the goal of many research groups is to create wearable devices able to monitor breathing activity continuously, under natural physiological conditions in different environments. Therefore, wearable sensors that have been used recently as well as the main signal processing methods for breathing analysis are discussed. The following sensor technologies are presented: acoustic, resistive, inductive, humidity, acceleration, pressure, electromyography, impedance, and infrared. New technologies open the door to future methods of noninvasive breathing analysis using wearable sensors associated with machine learning techniques for pattern detection.",book:{id:"7654",slug:"wearable-devices-the-big-wave-of-innovation",title:"Wearable Devices",fullTitle:"Wearable Devices - the Big Wave of Innovation"},signatures:"Taisa Daiana da Costa, Maria de Fatima Fernandes Vara, Camila Santos Cristino, Tyene Zoraski Zanella, Guilherme Nunes Nogueira Neto and Percy Nohama",authors:[{id:"192464",title:"Ph.D.",name:"Percy",middleName:null,surname:"Nohama",slug:"percy-nohama",fullName:"Percy Nohama"},{id:"285706",title:"MSc.",name:"Taísa Daiana",middleName:null,surname:"Da Costa",slug:"taisa-daiana-da-costa",fullName:"Taísa Daiana Da Costa"},{id:"285707",title:"MSc.",name:"Maria de Fatima Fernandes",middleName:null,surname:"Vara",slug:"maria-de-fatima-fernandes-vara",fullName:"Maria de Fatima Fernandes Vara"},{id:"285708",title:"BSc.",name:"Camila Santos",middleName:null,surname:"Cristino",slug:"camila-santos-cristino",fullName:"Camila Santos Cristino"},{id:"285709",title:"Prof.",name:"Guilherme Nunes",middleName:null,surname:"Nogueira Neto",slug:"guilherme-nunes-nogueira-neto",fullName:"Guilherme Nunes Nogueira Neto"},{id:"293109",title:"BSc.",name:"Tyene",middleName:null,surname:"Zoraski Zanella",slug:"tyene-zoraski-zanella",fullName:"Tyene Zoraski Zanella"}]},{id:"41411",title:"Textile Dyes: Dyeing Process and Environmental Impact",slug:"textile-dyes-dyeing-process-and-environmental-impact",totalDownloads:20540,totalCrossrefCites:92,totalDimensionsCites:299,abstract:null,book:{id:"3137",slug:"eco-friendly-textile-dyeing-and-finishing",title:"Eco-Friendly Textile Dyeing and Finishing",fullTitle:"Eco-Friendly Textile Dyeing and Finishing"},signatures:"Farah Maria Drumond Chequer, Gisele Augusto Rodrigues de Oliveira, Elisa Raquel Anastácio Ferraz, Juliano Carvalho Cardoso, Maria Valnice Boldrin Zanoni and Danielle Palma de Oliveira",authors:[{id:"49040",title:"Prof.",name:"Danielle",middleName:null,surname:"Palma De Oliveira",slug:"danielle-palma-de-oliveira",fullName:"Danielle Palma De Oliveira"},{id:"149074",title:"Prof.",name:"Maria Valnice",middleName:null,surname:"Zanoni",slug:"maria-valnice-zanoni",fullName:"Maria Valnice Zanoni"},{id:"153502",title:"Ph.D.",name:"Farah",middleName:null,surname:"Chequer",slug:"farah-chequer",fullName:"Farah Chequer"},{id:"153504",title:"MSc.",name:"Gisele",middleName:null,surname:"Oliveira",slug:"gisele-oliveira",fullName:"Gisele Oliveira"},{id:"163377",title:"Dr.",name:"Juliano",middleName:null,surname:"Cardoso",slug:"juliano-cardoso",fullName:"Juliano Cardoso"},{id:"163393",title:"Dr.",name:"Elisa",middleName:null,surname:"Ferraz",slug:"elisa-ferraz",fullName:"Elisa Ferraz"}]},{id:"70242",title:"Advancements in the Fenton Process for Wastewater Treatment",slug:"advancements-in-the-fenton-process-for-wastewater-treatment",totalDownloads:1892,totalCrossrefCites:10,totalDimensionsCites:23,abstract:"Fenton is considered to be one of the most effective advanced treatment processes in the removal of many hazardous organic pollutants from refractory/toxic wastewater. It has many advantages, but drawbacks are significant such as a strong acid environment, the cost of reagents consumption, and the large production of ferric sludge, which limits Fenton’s further application. The development of Fenton applications is mainly achieved by improving oxidation efficiency and reducing sludge production. This chapter presents a review on fundamentals and applications of conventional Fenton, leading advanced technologies in the Fenton process, and reuse methods of iron containing sludge to synthetic and real wastewaters are discussed. Finally, future trends and some guidelines for Fenton processes are given.",book:{id:"9415",slug:"advanced-oxidation-processes-applications-trends-and-prospects",title:"Advanced Oxidation Processes",fullTitle:"Advanced Oxidation Processes - Applications, Trends, and Prospects"},signatures:"Min Xu, Changyong Wu and Yuexi Zhou",authors:[{id:"307479",title:"Dr.",name:"Changyong",middleName:null,surname:"Wu",slug:"changyong-wu",fullName:"Changyong Wu"},{id:"307546",title:"Prof.",name:"Yuexi",middleName:null,surname:"Zhou",slug:"yuexi-zhou",fullName:"Yuexi Zhou"},{id:"311139",title:"Dr.",name:"Min",middleName:null,surname:"Xu",slug:"min-xu",fullName:"Min Xu"}]}],onlineFirstChaptersFilter:{topicId:"24",limit:6,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},subscriptionForm:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[],offset:0,limit:8,total:null},allSeries:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:9,numberOfPublishedChapters:87,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:98,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:27,numberOfPublishedChapters:288,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:9,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:11,numberOfPublishedChapters:139,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:8,numberOfPublishedChapters:129,numberOfOpenTopics:0,numberOfUpcomingTopics:2,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!1},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:107,numberOfOpenTopics:3,numberOfUpcomingTopics:1,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:10,numberOfPublishedChapters:103,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:12,numberOfOpenTopics:2,numberOfUpcomingTopics:1,issn:"2753-894X",doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:0,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!1},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:0,numberOfPublishedChapters:11,numberOfOpenTopics:4,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],testimonialsList:[{id:"6",text:"It is great to work with the IntechOpen to produce a worthwhile collection of research that also becomes a great educational resource and guide for future research endeavors.",author:{id:"259298",name:"Edward",surname:"Narayan",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/259298/images/system/259298.jpeg",slug:"edward-narayan",institution:{id:"3",name:"University of Queensland",country:{id:null,name:"Australia"}}}},{id:"13",text:"The collaboration with and support of the technical staff of IntechOpen is fantastic. The whole process of submitting an article and editing of the submitted article goes extremely smooth and fast, the number of reads and downloads of chapters is high, and the contributions are also frequently cited.",author:{id:"55578",name:"Antonio",surname:"Jurado-Navas",institutionString:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRisIQAS/Profile_Picture_1626166543950",slug:"antonio-jurado-navas",institution:{id:"720",name:"University of Malaga",country:{id:null,name:"Spain"}}}}]},series:{item:{id:"11",title:"Biochemistry",doi:"10.5772/intechopen.72877",issn:"2632-0983",scope:"Biochemistry, the study of chemical transformations occurring within living organisms, impacts all areas of life sciences, from molecular crystallography and genetics to ecology, medicine, and population biology. Biochemistry examines macromolecules - proteins, nucleic acids, carbohydrates, and lipids – and their building blocks, structures, functions, and interactions. Much of biochemistry is devoted to enzymes, proteins that catalyze chemical reactions, enzyme structures, mechanisms of action and their roles within cells. Biochemistry also studies small signaling molecules, coenzymes, inhibitors, vitamins, and hormones, which play roles in life processes. Biochemical experimentation, besides coopting classical chemistry methods, e.g., chromatography, adopted new techniques, e.g., X-ray diffraction, electron microscopy, NMR, radioisotopes, and developed sophisticated microbial genetic tools, e.g., auxotroph mutants and their revertants, fermentation, etc. More recently, biochemistry embraced the ‘big data’ omics systems. Initial biochemical studies have been exclusively analytic: dissecting, purifying, and examining individual components of a biological system; in the apt words of Efraim Racker (1913 –1991), “Don’t waste clean thinking on dirty enzymes.” Today, however, biochemistry is becoming more agglomerative and comprehensive, setting out to integrate and describe entirely particular biological systems. The ‘big data’ metabolomics can define the complement of small molecules, e.g., in a soil or biofilm sample; proteomics can distinguish all the comprising proteins, e.g., serum; metagenomics can identify all the genes in a complex environment, e.g., the bovine rumen. This Biochemistry Series will address the current research on biomolecules and the emerging trends with great promise.",coverUrl:"https://cdn.intechopen.com/series/covers/11.jpg",latestPublicationDate:"May 24th, 2022",hasOnlineFirst:!0,numberOfPublishedBooks:27,editor:{id:"31610",title:"Dr.",name:"Miroslav",middleName:null,surname:"Blumenberg",slug:"miroslav-blumenberg",fullName:"Miroslav Blumenberg",profilePictureURL:"https://mts.intechopen.com/storage/users/31610/images/system/31610.jpg",biography:"Miroslav Blumenberg, Ph.D., was born in Subotica and received his BSc in Belgrade, Yugoslavia. He completed his Ph.D. at MIT in Organic Chemistry; he followed up his Ph.D. with two postdoctoral study periods at Stanford University. Since 1983, he has been a faculty member of the RO Perelman Department of Dermatology, NYU School of Medicine, where he is codirector of a training grant in cutaneous biology. Dr. Blumenberg’s research is focused on the epidermis, expression of keratin genes, transcription profiling, keratinocyte differentiation, inflammatory diseases and cancers, and most recently the effects of the microbiome on the skin. He has published more than 100 peer-reviewed research articles and graduated numerous Ph.D. and postdoctoral students.",institutionString:null,institution:{name:"New York University Langone Medical Center",institutionURL:null,country:{name:"United States of America"}}},editorTwo:null,editorThree:null},subseries:{paginationCount:4,paginationItems:[{id:"14",title:"Cell and Molecular Biology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/14.jpg",isOpenForSubmission:!0,editor:{id:"165627",title:"Dr.",name:"Rosa María",middleName:null,surname:"Martínez-Espinosa",slug:"rosa-maria-martinez-espinosa",fullName:"Rosa María Martínez-Espinosa",profilePictureURL:"https://mts.intechopen.com/storage/users/165627/images/system/165627.jpeg",biography:"Dr. Rosa María Martínez-Espinosa has been a Spanish Full Professor since 2020 (Biochemistry and Molecular Biology) and is currently Vice-President of International Relations and Cooperation development and leader of the research group 'Applied Biochemistry” (University of Alicante, Spain). Other positions she has held at the university include Vice-Dean of Master Programs, Vice-Dean of the Degree in Biology and Vice-Dean for Mobility and Enterprise and Engagement at the Faculty of Science (University of Alicante). She received her Bachelor in Biology in 1998 (University of Alicante) and her PhD in 2003 (Biochemistry, University of Alicante). She undertook post-doctoral research at the University of East Anglia (Norwich, U.K. 2004-2005; 2007-2008).\nHer multidisciplinary research focuses on investigating archaea and their potential applications in biotechnology. She has an H-index of 21. She has authored one patent and has published more than 70 indexed papers and around 60 book chapters.\nShe has contributed to more than 150 national and international meetings during the last 15 years. Her research interests include archaea metabolism, enzymes purification and characterization, gene regulation, carotenoids and bioplastics production, antioxidant\ncompounds, waste water treatments, and brines bioremediation.\nRosa María’s other roles include editorial board member for several journals related\nto biochemistry, reviewer for more than 60 journals (biochemistry, molecular biology, biotechnology, chemistry and microbiology) and president of several organizing committees in international meetings related to the N-cycle or respiratory processes.",institutionString:null,institution:{name:"University of Alicante",institutionURL:null,country:{name:"Spain"}}},editorTwo:null,editorThree:null},{id:"15",title:"Chemical Biology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/15.jpg",isOpenForSubmission:!0,editor:{id:"441442",title:"Dr.",name:"Şükrü",middleName:null,surname:"Beydemir",slug:"sukru-beydemir",fullName:"Şükrü Beydemir",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y00003GsUoIQAV/Profile_Picture_1634557147521",biography:"Dr. Şükrü Beydemir obtained a BSc in Chemistry in 1995 from Yüzüncü Yıl University, MSc in Biochemistry in 1998, and PhD in Biochemistry in 2002 from Atatürk University, Turkey. He performed post-doctoral studies at Max-Planck Institute, Germany, and University of Florence, Italy in addition to making several scientific visits abroad. He currently works as a Full Professor of Biochemistry in the Faculty of Pharmacy, Anadolu University, Turkey. Dr. Beydemir has published over a hundred scientific papers spanning protein biochemistry, enzymology and medicinal chemistry, reviews, book chapters and presented several conferences to scientists worldwide. He has received numerous publication awards from various international scientific councils. He serves in the Editorial Board of several international journals. Dr. Beydemir is also Rector of Bilecik Şeyh Edebali University, Turkey.",institutionString:null,institution:{name:"Anadolu University",institutionURL:null,country:{name:"Turkey"}}},editorTwo:{id:"13652",title:"Prof.",name:"Deniz",middleName:null,surname:"Ekinci",slug:"deniz-ekinci",fullName:"Deniz Ekinci",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYLT1QAO/Profile_Picture_1634557223079",biography:"Dr. Deniz Ekinci obtained a BSc in Chemistry in 2004, MSc in Biochemistry in 2006, and PhD in Biochemistry in 2009 from Atatürk University, Turkey. He studied at Stetson University, USA, in 2007-2008 and at the Max Planck Institute of Molecular Cell Biology and Genetics, Germany, in 2009-2010. Dr. Ekinci currently works as a Full Professor of Biochemistry in the Faculty of Agriculture and is the Head of the Enzyme and Microbial Biotechnology Division, Ondokuz Mayıs University, Turkey. He is a member of the Turkish Biochemical Society, American Chemical Society, and German Genetics society. Dr. Ekinci published around ninety scientific papers, reviews and book chapters, and presented several conferences to scientists. He has received numerous publication awards from several scientific councils. Dr. Ekinci serves as the Editor in Chief of four international books and is involved in the Editorial Board of several international journals.",institutionString:null,institution:{name:"Ondokuz Mayıs University",institutionURL:null,country:{name:"Turkey"}}},editorThree:null},{id:"17",title:"Metabolism",coverUrl:"https://cdn.intechopen.com/series_topics/covers/17.jpg",isOpenForSubmission:!0,editor:{id:"138626",title:"Dr.",name:"Yannis",middleName:null,surname:"Karamanos",slug:"yannis-karamanos",fullName:"Yannis Karamanos",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002g6Jv2QAE/Profile_Picture_1629356660984",biography:"Yannis Karamanos, born in Greece in 1953, completed his pre-graduate studies at the Université Pierre et Marie Curie, Paris, then his Masters and Doctoral degree at the Université de Lille (1983). He was associate professor at the University of Limoges (1987) before becoming full professor of biochemistry at the Université d’Artois (1996). He worked on the structure-function relationships of glycoconjugates and his main project was the investigations on the biological roles of the de-N-glycosylation enzymes (Endo-N-acetyl-β-D-glucosaminidase and peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidase). From 2002 he contributes to the understanding of the Blood-brain barrier functioning using proteomics approaches. He has published more than 70 papers. His teaching areas are energy metabolism and regulation, integration and organ specialization and metabolic adaptation.",institutionString:null,institution:{name:"Artois University",institutionURL:null,country:{name:"France"}}},editorTwo:null,editorThree:null},{id:"18",title:"Proteomics",coverUrl:"https://cdn.intechopen.com/series_topics/covers/18.jpg",isOpenForSubmission:!0,editor:{id:"200689",title:"Prof.",name:"Paolo",middleName:null,surname:"Iadarola",slug:"paolo-iadarola",fullName:"Paolo Iadarola",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bSCl8QAG/Profile_Picture_1623568118342",biography:"Paolo Iadarola graduated with a degree in Chemistry from the University of Pavia (Italy) in July 1972. He then worked as an Assistant Professor at the Faculty of Science of the same University until 1984. In 1985, Prof. Iadarola became Associate Professor at the Department of Biology and Biotechnologies of the University of Pavia and retired in October 2017. Since then, he has been working as an Adjunct Professor in the same Department at the University of Pavia. His research activity during the first years was primarily focused on the purification and structural characterization of enzymes from animal and plant sources. During this period, Prof. Iadarola familiarized himself with the conventional techniques used in column chromatography, spectrophotometry, manual Edman degradation, and electrophoresis). Since 1995, he has been working on: i) the determination in biological fluids (serum, urine, bronchoalveolar lavage, sputum) of proteolytic activities involved in the degradation processes of connective tissue matrix, and ii) on the identification of biological markers of lung diseases. In this context, he has developed and validated new methodologies (e.g., Capillary Electrophoresis coupled to Laser-Induced Fluorescence, CE-LIF) whose application enabled him to determine both the amounts of biochemical markers (Desmosines) in urine/serum of patients affected by Chronic Obstructive Pulmonary Disease (COPD) and the activity of proteolytic enzymes (Human Neutrophil Elastase, Cathepsin G, Pseudomonas aeruginosa elastase) in sputa of these patients. More recently, Prof. Iadarola was involved in developing techniques such as two-dimensional electrophoresis coupled to liquid chromatography/mass spectrometry (2DE-LC/MS) for the proteomic analysis of biological fluids aimed at the identification of potential biomarkers of different lung diseases. He is the author of about 150 publications (According to Scopus: H-Index: 23; Total citations: 1568- According to WOS: H-Index: 20; Total Citations: 1296) of peer-reviewed international journals. He is a Consultant Reviewer for several journals, including the Journal of Chromatography A, Journal of Chromatography B, Plos ONE, Proteomes, International Journal of Molecular Science, Biotech, Electrophoresis, and others. He is also Associate Editor of Biotech.",institutionString:null,institution:{name:"University of Pavia",institutionURL:null,country:{name:"Italy"}}},editorTwo:{id:"201414",title:"Dr.",name:"Simona",middleName:null,surname:"Viglio",slug:"simona-viglio",fullName:"Simona Viglio",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRKDHQA4/Profile_Picture_1630402531487",biography:"Simona Viglio is an Associate Professor of Biochemistry at the Department of Molecular Medicine at the University of Pavia. She has been working since 1995 on the determination of proteolytic enzymes involved in the degradation process of connective tissue matrix and on the identification of biological markers of lung diseases. She gained considerable experience in developing and validating new methodologies whose applications allowed her to determine both the amount of biomarkers (Desmosine and Isodesmosine) in the urine of patients affected by COPD, and the activity of proteolytic enzymes (HNE, Cathepsin G, Pseudomonas aeruginosa elastase) in the sputa of these patients. Simona Viglio was also involved in research dealing with the supplementation of amino acids in patients with brain injury and chronic heart failure. She is presently engaged in the development of 2-DE and LC-MS techniques for the study of proteomics in biological fluids. The aim of this research is the identification of potential biomarkers of lung diseases. She is an author of about 90 publications (According to Scopus: H-Index: 23; According to WOS: H-Index: 20) on peer-reviewed journals, a member of the “Società Italiana di Biochimica e Biologia Molecolare,“ and a Consultant Reviewer for International Journal of Molecular Science, Journal of Chromatography A, COPD, Plos ONE and Nutritional Neuroscience.",institutionString:null,institution:{name:"University of Pavia",institutionURL:null,country:{name:"Italy"}}},editorThree:null}]},overviewPageOFChapters:{paginationCount:50,paginationItems:[{id:"81927",title:"Purinergic System in Immune Response",doi:"10.5772/intechopen.104485",signatures:"Yerly Magnolia Useche Salvador",slug:"purinergic-system-in-immune-response",totalDownloads:0,totalCrossrefCites:null,totalDimensionsCites:null,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"80495",title:"Iron in Cell Metabolism and Disease",doi:"10.5772/intechopen.101908",signatures:"Eeka Prabhakar",slug:"iron-in-cell-metabolism-and-disease",totalDownloads:7,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Iron Metabolism - Iron a Double‐Edged Sword",coverURL:"https://cdn.intechopen.com/books/images_new/10842.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81799",title:"Cross Talk of Purinergic and Immune Signaling: Implication in Inflammatory and Pathogenic Diseases",doi:"10.5772/intechopen.104978",signatures:"Richa Rai",slug:"cross-talk-of-purinergic-and-immune-signaling-implication-in-inflammatory-and-pathogenic-diseases",totalDownloads:10,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81764",title:"Involvement of the Purinergic System in Cell Death in Models of Retinopathies",doi:"10.5772/intechopen.103935",signatures:"Douglas Penaforte Cruz, Marinna Garcia Repossi and Lucianne Fragel Madeira",slug:"involvement-of-the-purinergic-system-in-cell-death-in-models-of-retinopathies",totalDownloads:5,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}}]},overviewPagePublishedBooks:{paginationCount:27,paginationItems:[{type:"book",id:"7006",title:"Biochemistry and Health Benefits of Fatty Acids",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7006.jpg",slug:"biochemistry-and-health-benefits-of-fatty-acids",publishedDate:"December 19th 2018",editedByType:"Edited by",bookSignature:"Viduranga Waisundara",hash:"c93a00abd68b5eba67e5e719f67fd20b",volumeInSeries:1,fullTitle:"Biochemistry and Health Benefits of Fatty Acids",editors:[{id:"194281",title:"Dr.",name:"Viduranga Y.",middleName:null,surname:"Waisundara",slug:"viduranga-y.-waisundara",fullName:"Viduranga Y. Waisundara",profilePictureURL:"https://mts.intechopen.com/storage/users/194281/images/system/194281.jpg",biography:"Dr. Viduranga Waisundara obtained her Ph.D. in Food Science and Technology from the Department of Chemistry, National University of Singapore, in 2010. She was a lecturer at Temasek Polytechnic, Singapore from July 2009 to March 2013. She relocated to her motherland of Sri Lanka and spearheaded the Functional Food Product Development Project at the National Institute of Fundamental Studies from April 2013 to October 2016. She was a senior lecturer on a temporary basis at the Department of Food Technology, Faculty of Technology, Rajarata University of Sri Lanka. She is currently Deputy Principal of the Australian College of Business and Technology – Kandy Campus, Sri Lanka. She is also the Global Harmonization Initiative (GHI) Ambassador to Sri Lanka.",institutionString:"Australian College of Business & Technology",institution:null}]},{type:"book",id:"6820",title:"Keratin",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/6820.jpg",slug:"keratin",publishedDate:"December 19th 2018",editedByType:"Edited by",bookSignature:"Miroslav Blumenberg",hash:"6def75cd4b6b5324a02b6dc0359896d0",volumeInSeries:2,fullTitle:"Keratin",editors:[{id:"31610",title:"Dr.",name:"Miroslav",middleName:null,surname:"Blumenberg",slug:"miroslav-blumenberg",fullName:"Miroslav Blumenberg",profilePictureURL:"https://mts.intechopen.com/storage/users/31610/images/system/31610.jpg",biography:"Miroslav Blumenberg, Ph.D., was born in Subotica and received his BSc in Belgrade, Yugoslavia. He completed his Ph.D. at MIT in Organic Chemistry; he followed up his Ph.D. with two postdoctoral study periods at Stanford University. Since 1983, he has been a faculty member of the RO Perelman Department of Dermatology, NYU School of Medicine, where he is codirector of a training grant in cutaneous biology. Dr. Blumenberg’s research is focused on the epidermis, expression of keratin genes, transcription profiling, keratinocyte differentiation, inflammatory diseases and cancers, and most recently the effects of the microbiome on the skin. He has published more than 100 peer-reviewed research articles and graduated numerous Ph.D. and postdoctoral students.",institutionString:null,institution:{name:"New York University Langone Medical Center",institutionURL:null,country:{name:"United States of America"}}}]},{type:"book",id:"7978",title:"Vitamin A",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7978.jpg",slug:"vitamin-a",publishedDate:"May 15th 2019",editedByType:"Edited by",bookSignature:"Leila Queiroz Zepka, Veridiana Vera de Rosso and Eduardo Jacob-Lopes",hash:"dad04a658ab9e3d851d23705980a688b",volumeInSeries:3,fullTitle:"Vitamin A",editors:[{id:"261969",title:"Dr.",name:"Leila",middleName:null,surname:"Queiroz Zepka",slug:"leila-queiroz-zepka",fullName:"Leila Queiroz Zepka",profilePictureURL:"https://mts.intechopen.com/storage/users/261969/images/system/261969.png",biography:"Prof. Dr. Leila Queiroz Zepka is currently an associate professor in the Department of Food Technology and Science, Federal University of Santa Maria, Brazil. She has more than fifteen years of teaching and research experience. She has published more than 550 scientific publications/communications, including 15 books, 50 book chapters, 100 original research papers, 380 research communications in national and international conferences, and 12 patents. She is a member of the editorial board of five journals and acts as a reviewer for several national and international journals. Her research interests include microalgal biotechnology with an emphasis on microalgae-based products.",institutionString:"Universidade Federal de Santa Maria",institution:{name:"Universidade Federal de Santa Maria",institutionURL:null,country:{name:"Brazil"}}}]},{type:"book",id:"7953",title:"Bioluminescence",subtitle:"Analytical Applications and Basic Biology",coverURL:"https://cdn.intechopen.com/books/images_new/7953.jpg",slug:"bioluminescence-analytical-applications-and-basic-biology",publishedDate:"September 25th 2019",editedByType:"Edited by",bookSignature:"Hirobumi Suzuki",hash:"3a8efa00b71abea11bf01973dc589979",volumeInSeries:4,fullTitle:"Bioluminescence - Analytical Applications and Basic Biology",editors:[{id:"185746",title:"Dr.",name:"Hirobumi",middleName:null,surname:"Suzuki",slug:"hirobumi-suzuki",fullName:"Hirobumi Suzuki",profilePictureURL:"https://mts.intechopen.com/storage/users/185746/images/system/185746.png",biography:"Dr. Hirobumi Suzuki received his Ph.D. in 1997 from Tokyo Metropolitan University, Japan, where he studied firefly phylogeny and the evolution of mating systems. He is especially interested in the genetic differentiation pattern and speciation process that correlate to the flashing pattern and mating behavior of some fireflies in Japan. He then worked for Olympus Corporation, a Japanese manufacturer of optics and imaging products, where he was involved in the development of luminescence technology and produced a bioluminescence microscope that is currently being used for gene expression analysis in chronobiology, neurobiology, and developmental biology. Dr. Suzuki currently serves as a visiting researcher at Kogakuin University, Japan, and also a vice president of the Japan Firefly Society.",institutionString:"Kogakuin University",institution:null}]}]},openForSubmissionBooks:{},onlineFirstChapters:{},subseriesFiltersForOFChapters:[],publishedBooks:{},subseriesFiltersForPublishedBooks:[],publicationYearFilters:[],authors:{}},subseries:{item:{id:"12",type:"subseries",title:"Human Physiology",keywords:"Anatomy, Cells, Organs, Systems, Homeostasis, Functions",scope:"Human physiology is the scientific exploration of the various functions (physical, biochemical, and mechanical properties) of humans, their organs, and their constituent cells. The endocrine and nervous systems play important roles in maintaining homeostasis in the human body. Integration, which is the biological basis of physiology, is achieved through communication between the many overlapping functions of the human body's systems, which takes place through electrical and chemical means. Much of the basis of our knowledge of human physiology has been provided by animal experiments. Because of the close relationship between structure and function, studies in human physiology and anatomy seek to understand the mechanisms that help the human body function. The series on human physiology deals with the various mechanisms of interaction between the various organs, nerves, and cells in the human body.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/12.jpg",hasOnlineFirst:!0,hasPublishedBooks:!0,annualVolume:11408,editor:{id:"195829",title:"Prof.",name:"Kunihiro",middleName:null,surname:"Sakuma",slug:"kunihiro-sakuma",fullName:"Kunihiro Sakuma",profilePictureURL:"https://mts.intechopen.com/storage/users/195829/images/system/195829.jpg",biography:"Professor Kunihiro Sakuma, Ph.D., currently works in the Institute for Liberal Arts at the Tokyo Institute of Technology. He is a physiologist working in the field of skeletal muscle. He was awarded his sports science diploma in 1995 by the University of Tsukuba and began his scientific work at the Department of Physiology, Aichi Human Service Center, focusing on the molecular mechanism of congenital muscular dystrophy and normal muscle regeneration. His interest later turned to the molecular mechanism and attenuating strategy of sarcopenia (age-related muscle atrophy). His opinion is to attenuate sarcopenia by improving autophagic defects using nutrient- and pharmaceutical-based treatments.",institutionString:null,institution:{name:"Tokyo Institute of Technology",institutionURL:null,country:{name:"Japan"}}},editorTwo:null,editorThree:{id:"331519",title:"Dr.",name:"Kotomi",middleName:null,surname:"Sakai",slug:"kotomi-sakai",fullName:"Kotomi Sakai",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y000031QtFXQA0/Profile_Picture_1637053227318",biography:"Senior researcher Kotomi Sakai, Ph.D., MPH, works at the Research Organization of Science and Technology in Ritsumeikan University. She is a researcher in the geriatric rehabilitation and public health field. She received Ph.D. from Nihon University and MPH from St.Luke’s International University. Her main research interest is sarcopenia in older adults, especially its association with nutritional status. Additionally, to understand how to maintain and improve physical function in older adults, to conduct studies about the mechanism of sarcopenia and determine when possible interventions are needed.",institutionString:null,institution:{name:"Ritsumeikan University",institutionURL:null,country:{name:"Japan"}}},series:{id:"10",title:"Physiology",doi:"10.5772/intechopen.72796",issn:"2631-8261"},editorialBoard:[{id:"213786",title:"Dr.",name:"Henrique P.",middleName:null,surname:"Neiva",slug:"henrique-p.-neiva",fullName:"Henrique P. Neiva",profilePictureURL:"https://mts.intechopen.com/storage/users/213786/images/system/213786.png",institutionString:null,institution:{name:"University of Beira Interior",institutionURL:null,country:{name:"Portugal"}}},{id:"39275",title:"Prof.",name:"Herbert Ryan",middleName:null,surname:"Marini",slug:"herbert-ryan-marini",fullName:"Herbert Ryan Marini",profilePictureURL:"https://mts.intechopen.com/storage/users/39275/images/9459_n.jpg",institutionString:null,institution:{name:"University of Messina",institutionURL:null,country:{name:"Italy"}}},{id:"196218",title:"Dr.",name:"Pasquale",middleName:null,surname:"Cianci",slug:"pasquale-cianci",fullName:"Pasquale Cianci",profilePictureURL:"https://mts.intechopen.com/storage/users/196218/images/system/196218.png",institutionString:null,institution:{name:"University of Foggia",institutionURL:null,country:{name:"Italy"}}}]},onlineFirstChapters:{},publishedBooks:{},testimonialsList:[{id:"18",text:"It was great publishing with IntechOpen, the process was straightforward and I had support all along.",author:{id:"71579",name:"Berend",surname:"Olivier",institutionString:"Utrecht University",profilePictureURL:"https://mts.intechopen.com/storage/users/71579/images/system/71579.png",slug:"berend-olivier",institution:{id:"253",name:"Utrecht University",country:{id:null,name:"Netherlands"}}}},{id:"27",text:"The opportunity to work with a prestigious publisher allows for the possibility to collaborate with more research groups interested in animal nutrition, leading to the development of new feeding strategies and food valuation while being more sustainable with the environment, allowing more readers to learn about the subject.",author:{id:"175967",name:"Manuel",surname:"Gonzalez Ronquillo",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/175967/images/system/175967.png",slug:"manuel-gonzalez-ronquillo",institution:{id:"6221",name:"Universidad Autónoma del Estado de México",country:{id:null,name:"Mexico"}}}},{id:"8",text:"I work with IntechOpen for a number of reasons: their professionalism, their mission in support of Open Access publishing, and the quality of their peer-reviewed publications, but also because they believe in equality.",author:{id:"202192",name:"Catrin",surname:"Rutland",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/202192/images/system/202192.png",slug:"catrin-rutland",institution:{id:"134",name:"University of Nottingham",country:{id:null,name:"United Kingdom"}}}}]},submityourwork:{pteSeriesList:[],lsSeriesList:[],hsSeriesList:[],sshSeriesList:[],subseriesList:[],annualVolumeBook:{},thematicCollection:[],selectedSeries:null,selectedSubseries:null},seriesLanding:{item:null},libraryRecommendation:{success:null,errors:{},institutions:[]},route:{name:"profile.detail",path:"/profiles/345542",hash:"",query:{},params:{id:"345542"},fullPath:"/profiles/345542",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()